US20210030024A1 - Compositions and methods for introduction of odd-chain fatty acids into poultry eggs - Google Patents
Compositions and methods for introduction of odd-chain fatty acids into poultry eggs Download PDFInfo
- Publication number
- US20210030024A1 US20210030024A1 US17/073,075 US202017073075A US2021030024A1 US 20210030024 A1 US20210030024 A1 US 20210030024A1 US 202017073075 A US202017073075 A US 202017073075A US 2021030024 A1 US2021030024 A1 US 2021030024A1
- Authority
- US
- United States
- Prior art keywords
- ocfa
- poultry
- thraustochytrid
- heptadecanoic
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000013601 eggs Nutrition 0.000 title claims abstract description 140
- 244000144977 poultry Species 0.000 title claims abstract description 121
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 104
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 104
- 239000000194 fatty acid Substances 0.000 title claims abstract description 104
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 103
- 238000000034 method Methods 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 claims abstract description 88
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 59
- 239000002028 Biomass Substances 0.000 claims abstract description 45
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 20
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 68
- 210000004027 cell Anatomy 0.000 claims description 43
- 241001467333 Thraustochytriaceae Species 0.000 claims description 41
- 235000019260 propionic acid Nutrition 0.000 claims description 33
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 33
- 239000001963 growth medium Substances 0.000 claims description 19
- 238000012258 culturing Methods 0.000 claims description 17
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 10
- 230000003816 axenic effect Effects 0.000 claims description 10
- 230000012010 growth Effects 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- 235000013345 egg yolk Nutrition 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 241001130339 Aurantiochytrium sp. Species 0.000 claims description 4
- 102000002322 Egg Proteins Human genes 0.000 claims description 4
- 108010000912 Egg Proteins Proteins 0.000 claims description 4
- 241000170101 Oblongichytrium sp. Species 0.000 claims description 4
- 241000598397 Schizochytrium sp. Species 0.000 claims description 4
- 241001298230 Thraustochytrium sp. Species 0.000 claims description 4
- 239000008121 dextrose Substances 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 abstract description 9
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 230000000378 dietary effect Effects 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 2
- 239000000284 extract Substances 0.000 abstract description 2
- 235000013594 poultry meat Nutrition 0.000 description 100
- 241000287828 Gallus gallus Species 0.000 description 66
- 235000013330 chicken meat Nutrition 0.000 description 66
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 50
- 241001306132 Aurantiochytrium Species 0.000 description 39
- 238000012360 testing method Methods 0.000 description 27
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 26
- 239000003921 oil Substances 0.000 description 26
- 229940090949 docosahexaenoic acid Drugs 0.000 description 25
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 11
- 230000008901 benefit Effects 0.000 description 9
- 239000003925 fat Substances 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 241000233671 Schizochytrium Species 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 235000014121 butter Nutrition 0.000 description 6
- 235000013365 dairy product Nutrition 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 241000195493 Cryptophyta Species 0.000 description 5
- 241000282849 Ruminantia Species 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 4
- -1 8% TFA) Chemical compound 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 3
- 241001491666 Labyrinthulomycetes Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001306135 Oblongichytrium Species 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000010411 cooking Methods 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- 230000004136 fatty acid synthesis Effects 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 235000006486 human diet Nutrition 0.000 description 3
- 239000002417 nutraceutical Substances 0.000 description 3
- 235000021436 nutraceutical agent Nutrition 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 2
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 2
- PZJLFHDNXGAZHU-UHFFFAOYSA-N 2,3-di(pentanoyloxy)propyl pentanoate Chemical compound CCCCC(=O)OCC(OC(=O)CCCC)COC(=O)CCCC PZJLFHDNXGAZHU-UHFFFAOYSA-N 0.000 description 2
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 2
- 101710146995 Acyl carrier protein Proteins 0.000 description 2
- 208000021873 Adult polyglucosan body disease Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 108010018763 Biotin carboxylase Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 2
- 241000233675 Thraustochytrium Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 208000029560 autism spectrum disease Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000000991 chicken egg Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000007483 microbial process Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- PJHKBYALYHRYSK-UHFFFAOYSA-N triheptanoin Chemical compound CCCCCCC(=O)OCC(OC(=O)CCCCCC)COC(=O)CCCCCC PJHKBYALYHRYSK-UHFFFAOYSA-N 0.000 description 2
- 229940078561 triheptanoin Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 108700037654 Acyl carrier protein (ACP) Proteins 0.000 description 1
- 102000048456 Acyl carrier protein (ACP) Human genes 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 108700005858 Carnitine palmitoyl transferase 2 deficiency Proteins 0.000 description 1
- 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000195651 Chlorella sp. Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000199914 Dinophyceae Species 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 101100393884 Drosophila melanogaster Glut1 gene Proteins 0.000 description 1
- YPZRHBJKEMOYQH-UYBVJOGSSA-L FADH2(2-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-L 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241001646653 Galdieria Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000168525 Haematococcus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124105 Isochrysis sp. Species 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000586743 Micractinium Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 241001302393 Porphyridium sp. Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 101150058068 SLC2A1 gene Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- KQLYFVFFPVJGRM-NBTZWHCOSA-N azanium;(9z,12z)-octadeca-9,12-dienoate Chemical compound [NH4+].CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O KQLYFVFFPVJGRM-NBTZWHCOSA-N 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 230000010035 cardiometabolic health Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000000346 malonyl group Chemical group C(CC(=O)*)(=O)* 0.000 description 1
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- QAQREVBBADEHPA-IEXPHMLFSA-N propionyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QAQREVBBADEHPA-IEXPHMLFSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 150000004669 very long chain fatty acids Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
Definitions
- This application relates generally to uses for microalgae biomass rich in odd-chain fatty acid and, more specifically, to compositions and methods for introduction of odd-chain fatty acids into poultry eggs.
- the citric acid cycle can govern the energy metabolism in aerobic organisms by producing 2 CO2, 3 NADH, 1 FADH2, and 1 ATP from the oxidation of acetyl-coA at every turn of the cycle.
- the cycle can provide precursors for biosynthesis of several amino acids, lipids, chlorophyll and other growth-related metabolites.
- the citric acid cycle is non-catalytic, which means that molecules used in biosynthesis are replenished so that the cycle can keep generating energy. Regardless of how much acetyl CoA is fed into the citric acid cycle, the cycle is able to produce merely a limited amount of citric acid intermediates.
- Anaplerotic substrates can be used to produce intermediates that are used to replenish the oxidative capacity of the citric acid cycle.
- Anaplerosis refers to the process of replenishing the citric acid cycle intermediates and restoring energy balance of the cell (metabolic homeostasis).
- Odd-chain fatty acids can be considered anaplerotic because, along with acetate units, they can also release propionic acid which can enter the citric acid cycle through the methylmalonate pathway (OCFA catabolism).
- Typical dietary sources of OCFA are milk and butter, but they have only trace amounts ( ⁇ 2% total fatty acids, TFA) of pentadecanoic (C15:0) and heptadecanoic (C17:0) acid.
- Synthetically produced concentrated sources such as tripentanoin and triheptanoin (e.g., oils containing C5:0 and C7:0), are not considered nutritional lipids.
- current methods that involve the use of Yarrowia lipolytica to produce odd-chain fatty acids utilize genetic modification.
- Odd-chain fatty acids are known to have potential health benefits including, but not limited to, reduction of incidence of type 2 diabetes, heart disease, and stroke as well as reducing incidence of neuro-degenerative diseases such as Alzheimer's disease and Lou Gehrig's disease.
- a primary constraint with OCFAs is the lack of their cost-effective availability.
- compositions rich in odd-chain fatty acids including pentadecanoic (C15:0) and heptadecanoic (C17:0) fatty acids, and products rich in pentadecanoic and heptadecanoic fatty acids derived from microalgae.
- the total fatty acid profile of the composition includes a fraction comprising at least about sixty percent (60%) odd-chain fatty acids (OCFA), and about twenty-five (25%) docosahexaenoic acid (DHA).
- microalgae and/or compositions rich in pentadecanoic and heptadecanoic acids may be used as a poultry feed or poultry feed ingredient.
- Methods and systems for increasing the production or concentration of pentadecanoic and heptadecanoic fatty acids from microalgae are also disclosed herein.
- OCFA in eggs such as poultry eggs.
- a biomass or oil rich in OCFA can be incorporated into poultry feed and fed to the egg-laying poultry.
- the OCFA in the feed fed to the poultry animals can result in an increase in the OCFA concentration in the fatty acid profile of the yolk of a resulting egg laid by the poultry animal.
- a poultry feed can be mixed with a compound derived from microalgae that is rich in OCFA.
- the resulting mixed poultry feed that is rich in OCFA can be fed to poultry to produce eggs that are rich in OCFA.
- the OCFA eggs can be consumed by humans as a source of OCFA in their diet to improve health.
- an OCFA-enriched poultry feed having an elevated level of odd-chain fatty acid comprises: poultry feed; and a microalgae compound produced from culturing microalgae to produce microalgae with elevated levels of odd-chain fatty acid, the microalgae compound comprising one of a biomass and an extracted oil; and wherein the microalgae compound is mixed with the poultry feed at an inclusion rate greater than one percent of a resulting OCFA-enriched poultry feed.
- a poultry egg comprises an elevated level of OCFA, the elevated level comprising an amount greater than 3% percent of the fatty acid profile of the yolk, wherein the poultry egg was laid by a poultry animal having been fed an OCFA-enriched poultry feed composition comprising an effective amount of an OCFA-rich microalgae compound.
- a method for producing a poultry egg with an elevated amount of odd-chain fatty acid comprises: mixing a desired amount of OCFA-rich microalgae compound into poultry feed resulting in OCFA-enriched feed composition, the desired amount comprising greater than one percent of the OCFA-enriched feed; feeding the OCFA-enriched feed composition to poultry that lays eggs; and retrieving an egg produced by the poultry, the egg comprising an elevated amount of OCFA in the lipid profile of the yolk.
- OCFA odd-chain fatty acid
- FIG. 1 is a line graph showing the fatty acid composition (in percent TFA) of various fatty acids in the eggs of the test group chickens;
- FIG. 2 is a line graph showing the fatty acid composition (in percent TFA) of various fatty acids in the eggs of the control group chickens;
- FIG. 3 is a line graph showing the mg of OCFA and DHA calculated for each egg of the test group chickens based on the compositional profile and the total fat content of each egg;
- FIG. 4 is a line graph showing the weight of both control group chicken eggs and test group chicken eggs over time.
- FIG. 5 is a bar graph detailing the results of a blind taste test evaluation of the OCFA-enriched poultry eggs versus the eggs of the control group chickens.
- microalgae refers to microscopic single cell organisms such as microalgae, cyanobacteria, algae, diatoms, dinoflagellates, freshwater organisms, marine organisms, or other similar single cell organisms capable of growth in phototrophic, mixotrophic, or heterotrophic culture conditions.
- biomass means a composition wherein substantially all of the components of the microalgae cells produced in the composition during culturing/growth remain present (e.g., in certain aspects of the invention at least about 90% of the cellular components, at least about 95% of the cellular components, or at least about 99% of the cellular components produced during growth/culturing remain present).
- the microalgae biomass or extracts may be sourced from the class Labyrinthulomycetes to make a composition that may be used to increase odd-chain fatty acid concentrations in poultry eggs.
- the class Labyrinthulomycetes includes species of Schizochytrium and Aurantiochytrium.
- Non-limiting examples of microalgae genus and species that can be used in the compositions and methods of the claimed subject matter include: Aurantiochytrium sp., Aurantiochytrium acetophilum HS399, Chlorella sp., Haematococcus sp., Galdieria sp., Isochrysis sp., Micractinium sp., Porphyridium sp., Schizochytrium sp., Thraustochytrium sp., and Oblongichytrium sp.
- Taxonomic classification has been in flux for organisms in the genus Schizochytrium . Some organisms previously classified as Schizochytrium have been reclassified as Aurantiochytrium, Thraustochytrium , or Oblongichytrium . See Yokoyama et al. Taxonomic rearrangement of the genus Schizochytrium sensu lato based on morphology, chemotaxonomic characteristics, and 18S rRNA gene phylogeny (Thrausochytriaceae, Labyrinthulomycetes): emendation for Schizochytrium and erection of Aurantiochytrium and Oblongichytrium gen. nov.
- the microalgae may be cultured in phototrophic, mixotrophic, or heterotrophic culture conditions in an aqueous culture medium.
- the microalgae is Aurantiochytrium acetophilum HS399
- the Aurantiochytrium acetophilum HS399 is may be cultured in either mixotrophic or heterotrophic culture conditions in an aqueous culture medium.
- the organic carbon sources suitable for growing microalgae mixotrophically or heterotrophically may comprise: acetate, acetic acid, ammonium linoleate, arabinose, arginine, aspartic acid, butyric acid, cellulose, citric acid, ethanol, fructose, fatty acids, galactose, glucose, glycerol, glycine, lactic acid, lactose, maleic acid, maltose, mannose, methanol, molasses, peptone, plant based hydrolyzate, proline, propionic acid, ribose, sacchrose, partial or complete hydrolysates of starch, sucrose, tartaric, TCA-cycle organic acids, thin stillage, urea, industrial waste solutions, yeast extract, and combinations thereof.
- the organic carbon source may comprise any single source, combination of sources, and dilutions of single sources or combinations of sources.
- the microalgae may be cultured in axenic conditions. In some embodiments, the microalgae may be cultured in non-axenic conditions.
- Anaplerosis refers to the replenishment of the citric acid intermediates that have been extracted by the cell for biosynthesis.
- Anaplerotic substrates such as glucose, protein and odd-chain fatty acids, could be converted into citric acid intermediates to restore an energy imbalance of the cell.
- OCFAs are different from other anaplerotic substrates because they can undergo ketosis and cross the blood-brain barrier. Therefore, OCFAs have been associated with a decrease in metabolic disease risk, and their intake has been proposed for the treatment and prevention of various gene and brain disorders.
- OCFAs in diet is scarce and typically limited to ruminant fat (e.g., butter), which contains only trace amounts ( ⁇ 2% total fatty acid (TFA)) of pentadecanoic acid (C15:0) and heptadecanoic acid (17:0).
- ruminant fat e.g., butter
- TFA total fatty acid
- Existing pharma OCFAs such as tripentanoin and triheptanoin oils, are produced synthetically, and are made of fatty acids that are not typically present in a human diet.
- a microbial process may be devised that can result in a natural algal oil comprising large (>50 TFA) quantities of dietary (C15:0 and C17:0) OCFAs.
- Typical anaplerotic substrates can include pyruvate (e.g., derived from carbohydrates), glutamine/glutamate (e.g., derived from protein) and precursors of propionyl-CoA, such as odd-chain fatty acids.
- Anaplerotic substrates can be used to restore energy balance in the mitochondria; and, there is a wide range of pathologies to which odd-chain fatty acids may provide benefits.
- odd-chain fatty acids have been experimentally used to treat: gene metabolic disorders, such as Glut1 deficiency, Fatty Acid Oxidation Disorder (FAOD), Pyruvate Carboxylase Deficiency, Carnitine Palmitoyltransferase II Deficiency, Huntington, Phenylketonuria, Adult Polyglucosan Body Disease (APBD), and Long-Chain Fat Oxidation Disorders; neural disorders, such as Epilepsy, Alzheimer's Disease, and Autism Spectrum Disorder (ASD); and circulatory system disorders, such as Ventricular Hypertrophy, and stroke.
- gene metabolic disorders such as Glut1 deficiency, Fatty Acid Oxidation Disorder (FAOD), Pyruvate Carboxylase Deficiency, Carnitine Palmitoyltransferase II Deficiency, Huntington, Phenylketonuria, Adult Polyglucosan Body Disease (APBD), and Long-Chain Fat Oxidation Disorders
- neural disorders
- pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0), also known as margaric acid may be derived from ruminant fat (e.g., butter), and are thought to be likely derived from bacterial activity in the rumen of dairy producing animals. These OCFAs can be found in very small amounts (e.g., ⁇ 2% total fatty acids (TFA)) in some dairy products (e.g., milk and butter).
- Pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) have also been found to be produced in the human gut, which may be triggered by dietary fiber intake, presumably supporting bacterial activity.
- odd-chain fatty acids e.g., C15:0 and C17:0
- compositions can be created that comprise a higher concentration than current sources of odd-chain fatty acids such as pentadecanoic and heptadecanoic fatty acids.
- a method can be devised for efficient and affective generation of such fatty acids from a newly derived source.
- Microalgae can produce a variety of fatty acids, the composition of which can vary among different strains.
- thraustochytrids can accumulate lipids up to eighty-five (85%) of their dry weight; and, amongst the oleaginous microorganisms, they may be one of the fastest growing.
- these organisms can be adapted to fermentation conditions (e.g., low shear sensitivity, high osmotolerance) for use in industrial production of microbe-based oils.
- Aurantiochytrium acetophilum HS399 is a thraustochytrid that can produce an oil containing palmitic acid (e.g., 45% total fatty acids (TFA)), n-6 docosapentaenoic acid (e.g., 8% TFA), and n-3 docosahexaenoic (e.g., 40% TFA) as the main fatty acids, with other fatty acids present in trace amounts.
- a live culture of the Aurantiochytrium acetophilum HS399 microalgae strain described herein was deposited on Sep. 12, 2019 at National Center for Marine Algae and Microbiota (NCMA), located at 60 Bigelow Drive, East Boothbay, Me. 04544, USA and received accession number 201909001.
- NCMA National Center for Marine Algae and Microbiota
- the trace fatty acids of HS399 can include pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) (e.g., at ⁇ 0.3% TFA).
- the trace fatty acids, including these two identified fatty acids, are typically ignored in the lipid profile reports for these organisms.
- Odd-chain fatty acids, including pentadecanoic acid and heptadecanoic acid are fatty acids that contain an odd number of carbon atoms in the structure. Pentadecanoic acid and heptadecanoic acid are both considered long chain fatty acids because they both contain more than 12 carbon atoms.
- OCFAs are typically related to bacterial activity (i.e. propionic acid bacteria), and are less likely to be present in algae or plants. Ref. 2
- Aurantiochytrium acetophilum HS399 naturally contains trace amounts of C15:0. The presence of trace amounts in Aurantiochytrium acetophilum HS399 suggests that the pathway responsible for the synthesis of OCFA may be present in Aurantiochytrium acetophilum HS399. Because of the composition of their fatty acid profile, and their ability to be grown rapidly, microalgae such as Aurantiochytrium acetophilum HS399 provide an attractive source of odd-chain fatty acids by generating odd-chain fatty acids in a more concentrated manner than other known natural sources, such as milk fat (e.g., providing a more cost effective and efficient source of OCFA).
- microalgae oil lacks residues of phytol or phytanic acid that are often present in ruminant fat. Consumption of phytol or phytanic acid can lead to health concerns in some individuals.
- microalgae and/or isolated composition may be used individually as products or as an ingredient in a variety of products.
- microalgae such as Aurantiochytrium acetophilum HS399 can be cultivated to produce a desirable fatty acid profile comprising OCFAs, which may be isolated through various extraction processes.
- the isolated oil containing the OCFAs may comprise a composition rich in OCFAs, such as pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0).
- the microalgae may be cultivated using an improved method that includes the presence of a complex media, which can promote increased production of the OCFAs.
- propionic acid e.g., and or one or more propionates, such as the anion, salts, and/or esters of propionic acid
- OCFA propionic acid
- Aurantiochytrium acetophilum HS399 can incorporate propionic acid in its lipid generation pathway, resulting in the production of OCFAs.
- fatty acid synthesis in microalgae consists of a lipid synthesis pathway involving acetyl CoA, and some metabolic cycles.
- acetyl-coenzyme A (CoA) is a universal carbon donor for fatty acid biosynthesis.
- Acetyl-CoA can be supplied be multiple paths, from various origins, and then subsequently metabolized into malonyl-acyl carrier protein (ACP) (or Malonyl CoA) by sequential reactions (e.g., utilizing acetyl-CoA carboxylase (ACCase) in carboxylation of A CoA).
- ACP malonyl-acyl carrier protein
- ACCase acetyl-CoA carboxylase
- fatty acid synthesis follows, resulting in the production of the fatty acids.
- the genome of Aurantiochytrium acetophilum HS399 suggests that saturated fats are synthetized through the Fatty Acid Synthase (FAS) pathway that uses acetyl-coA as a building block for the fatty acid elongation.
- Fatty Acid Synthase Fatty Acid Synthase
- the production of even chain fatty acids uses a malonyl-ACP as a substrate for elongation.
- the acyl carrier protein (ACP) cleaves to methylmalonyl instead of malonyl, resulting in the FAS producing of odd-chain fatty acids instead of even chain fatty acids.
- Palmitic acid (C16:0) is typically the primary even chain fatty acid in HS399, while the primary OCFAs is typically pentadecaenoic (C15:0) instead of heptadecanoic acid (17:0).
- fatty acid synthesis of palmitic acid (C16:0) undergoes 6 consecutive elongation cycles, while the (C15:0) OCFA undergoes only 5 elongation cycles before the fatty acid is liberated from the acyl carrier protein.
- a microbial process may be used to culture microalgae, which can result in a microalgae biomass and/or microalgae oil comprising large (>50 TFA) quantities of dietary OCFA (C15:0 and C17:0). Such quantities of dietary OCFA (C15:0 and C17:0) are significantly higher than what is found in the naturally occurring microalgae.
- propionic acid e.g., and/or propionates
- microalgae such as Aurantiochytrium acetophilum HS399
- Propionic acid may then be added to the culture medium comprising the Aurantiochytrium acetophilum HS399 in a batch, continuous feed, or fed-batch process, and cultured in a bioreactor with the culture medium.
- the Aurantiochytrium acetophilum HS399 cells were cultured in a two-stage axenic process which first feeds DE95 (which comprises about 95% dextrose) as a growth carbon source and then, after a specified period of time, feeds propionate to the microalgae, which causes the microalgae to produce OCFA as a part of its fatty acid profile.
- DE95 which comprises about 95% dextrose
- propionate to the microalgae, which causes the microalgae to produce OCFA as a part of its fatty acid profile.
- the “two-stage axenic process” refers to the first stage wherein propionate is not fed to the microalgae and the second stage wherein propionate is fed to the microalgae.
- the propionic acid can be added at a ratio of at least 0.05 g of propionic acid per gram of Aurantiochytrium acetophilum HS399 biomass, in order to accumulate elevated amounts of OCFA. In one embodiment, 0.15 g of propionic acid is added per gram of Aurantiochytrium acetophilum HS399 biomass, in order to accumulate OCFA above 50% TFA. In another implementation, the propionic acid can be added at a rate of above zero and up to about 3 g/L per day. In one implementation, the propionic acid can be added at a rate of above zero and up to about 3 g/L per day for three days, resulting in a total propionic acid addition of about 9 g/L.
- adding the propionate can comprise adding the propionate in a fed-batch approach into the culture medium. In one embodiment, adding the propionate can comprise adjusting the propionate fed to produce OCFAs in a range of 5 and 70% TFAs.
- anaplerotic oil containing concentrated amounts of OCFA can be extracted from the Aurantiochytrium acetophilum HS399. In one embodiment, anaplerotic oil can be produced from the cultured microalgae, wherein at least five percent of the total fatty acids (TFA) of the anaplerotic oil are OCFAs, and OCFAs make up at least one percent cell dry weight (CDW) of the anaplerotic oil.
- TFA total fatty acids
- CDW cell dry weight
- the Aurantiochytrium acetophilum HS399 cells After the Aurantiochytrium acetophilum HS399 cells achieved the desired OCFA profile, they were harvested, washed (i.e. diluted with water in a ratio of 2:1 and centrifuged in order to remove dissolved material and small particles), and then dried with NATUROX® antioxidant thus forming the Aurantiochytrium acetophilum HS399 biomass used in the experiments described herein. It should be clearly understood that other variations of the Aurantiochytrium acetophilum HS399 biomass microalgae, including variations in the microalgae strains, microalgae growth or processing methods, or variations in the stabilizers, may be used and may achieve similar results.
- the anaplerotic oil produced by microalgae can contain a substantial amount of DHA, which is a valuable nutraceutical.
- DHA docosahexaenoic acid
- CAD coronary artery disease
- ADHD attention deficit-hyperactivity disorder
- DHA can be converted into eicosapentaenoic acid (EPA) in the body, which is used in the prevention and reversal of heart disease, stabilizing heart rhythm, asthma, cancer, painful menstrual periods, hay fever, lung diseases, systemic lupus erythematosus (SLE), and certain kidney diseases.
- EPA and DHA have been used in combination to treat high cholesterol, high blood pressure, psoriasis, Raynaud's syndrome, rheumatoid arthritis, bipolar disorder, certain inflammations of the digestive system (ulcerative colitis), and to prevent migraine headaches in teenagers.
- the anaplerotic oils produced by Aurantiochytrium acetophilum HS399 may contain OCFAs C15:0 and C17:0 at 60% TFA and DHA at about 25% TFA.
- the propionate fed approach can cause some growth inhibition in the microalgae, but may not result in a complete culture loss of the microalgae batch.
- the fed-batch approach may achieve similar cell densities and overall lipid accumulation as a similar control batch with no propionic acid fed, with merely a one-day difference.
- propionic acid may be fed into the algal culture batch on demand (e.g., automatically fed using a pH-auxostat fed batch system).
- propionic acid may be fed into the microalgal batch along with a carbon source (e.g., glucose, glycerol or acetate) at a ratio below 0.1 of weight to weight (w/w) of propionic acid to carbon source (propionic acid/carbon source ratio).
- a carbon source e.g., glucose, glycerol or acetate
- propionic acid may be fed along with the carbon source at a ratio below 0.05 w/w propionic acid to carbon source, to mitigate or avoid accumulation of propionate in the culture media.
- propionic acid may be fed into a culture at a culture pH higher than 5. A low pH increases the toxicity of propionic acid making it more difficult to balance the window between propionate incorporation and growth inhibition.
- microalgae e.g. Aurantiochytrium acetophilum HS399
- PCT/US2018/067104 Taberna et al.
- OCFAs as well as DHA
- the biomass rich in OCFA, and/or the oil rich in OCFA were processed into poultry feed and fed to layer chickens.
- the enriched feed can be fed to poultry animals, such as chickens, resulting in the incorporation of OCFA in the compositional profile of the poultry egg.
- the enriched eggs can be a vehicle for delivering the OCFA to human consumers.
- a healthier egg can be created which can provide positive benefits to the cardiometabolic health (e.g., heart disease, diabetes, and stroke) of the human consumers, at a lower cost than typical pharmaceutical or nutraceutical treatments.
- a biomass of microalgae rich in OCFA can be fed to poultry animal, such as chickens, directly or as a processed feed.
- the biomass can be fed directly to the poultry, for example, as a supplement to other feed.
- the biomass can be processed into a pelletized form and fed to the poultry, for example, as a supplement to other feed.
- the biomass can be combined with typical poultry feed, and the combination can be processed into a pelletized form as poultry feed.
- the increased amount of OCFA in whole biomass can be mixed with standard poultry food, for example, in the range of 1.5-6.3% inclusion of the biomass into the feed.
- the mixed feed can then be fed to the poultry (e.g., chickens).
- the poultry can eat the food, for example, for chickens at the standard 0.2-0.25 lbs. per day of total food intake.
- the OCFA can be incorporated into the developing egg, and will appear as part of the fatty acid compositional profile of the yolk of the resulting poultry egg.
- the whole biomass can be mixed with standard poultry food, for example, in the range of 1.5-6.3% inclusion of the biomass into the feed.
- the mixed feed can then be processed into pellets, which include the biomass rich in OCFA. Further, the pelletized mixed feed can be fed to the poultry, in a similar manner as above.
- oil derived from the biomass such as algal oil, comprising the elevated concentration of OCFA
- standard poultry food for example, in the range that may be the same as that of the whole biomass (e.g. 1.5-6.3% inclusion) or may be less than that of the whole biomass (e.g., 0.5% to 4% inclusion of the oil into the feed).
- the oil-feed mix can be fed to the poultry.
- the oil-feed mix can be processed into pellets, and fed to the poultry.
- the resulting egg produced by the poultry may include an increase in OCFA over eggs produced by poultry that are not subjected to the treated feed.
- the pathway for digestion of fat by a chicken results in approximately 50 to 65% of the fat intake directed to produce egg yolks. That is, for example, whatever fat the chicken intakes can end up in a resulting egg yolk.
- some of the OCFA eaten by poultry may not end up as OCFA in the resulting yolk.
- some fatty acids may be metabolized for energy, stored, or incorporated in muscle.
- the composition impact on the egg can be in the range of about 1% to 6.2% of total OCFA (C15:0 plus C17:0), of the total fatty acid profile of the egg.
- an OCFA-enriched poultry feed was created.
- a standard commercially available chicken feed e.g. PETCLUB Layer Crumbles
- a 2.6% inclusion rate of OCFA rich Aurantiochytrium acetophilum HS399 biomass was combined with the standard conventional feed, thus creating the OCFA-enriched poultry feed. This was accomplished by mixing the correct inclusion rate of OCFA rich Aurantiochytrium acetophilum HS399 biomass with the base feed evenly, and then forming the new composition into pellets for the subject chickens to consume.
- OCFA-rich Aurantiochytrium acetophilum HS399 biomass Although a 2.6% inclusion rate of OCFA-rich Aurantiochytrium acetophilum HS399 biomass was used in the experiment, it should be clearly understood that substantial benefit would be obtained by using an alternative rate such as 1.5-6.3% of inclusion of OCFA-rich Aurantiochytrium acetophilum HS399 biomass in the feed, which would likely result in about 250 mg to 1,000 mg of OCFA per egg.
- the % inclusion of the OCFA-rich Aurantiochytrium acetophilum HS399 biomass (or OCFA-rich Aurantiochytrium acetophilum HS399 oil) may be increased or decreased depending upon how much OCFA is desired to be present in the resulting egg yolk.
- the OCFA rich Aurantiochytrium acetophilum HS399 biomass used for this experiment had an elevated amount of C:15 and C:17, in particular.
- Table 1 shows a comparison of the fatty acid profiles of the standard conventional feed alone versus the OCFA-enriched poultry feed.
- the OCFA-enriched poultry feed contained 0.88% TFA of C15:0 while the standard conventional feed contained absolutely no C15:0 OCFA; furthermore, the OCFA-enriched poultry feed contained 0.84% TFA of C17:0 OCFA while the standard conventional feed only contained 0.12% TFA of C17:0 OCFA.
- 4-6 chickens were established as the control group.
- the control group was fed the standard commercially available base feed.
- the control group chickens were allowed to eat freely as they desired, which was at a rate of about 0.25 lbs/day/chicken.
- Another group of 4-6 chickens made up the test group.
- the test group was fed with the OCFA-enriched poultry feed, with contained the 2.6% inclusion of OCFA rich Aurantiochytrium acetophilum HS399 biomass.
- the test group chickens were also allowed to eat freely as they desired, which was also at a rate of about 0.25 lbs/day/chicken.
- Eggs from both the control group and the test group were collected either daily or every other day and were delivered for analysis twice per week on Mondays and Thursdays.
- egg yolks were separated from the egg whites and only the yolks were analyzed.
- the eggs were mixed at 3-6 eggs per every 2-3 day period, freeze dried, and then submitted for analysis.
- FIG. 1 is a line graph showing the fatty acid composition (in percent TFA) of various fatty acids in the eggs of the test group chickens throughout the test duration.
- the raw data gathered during the experiment is presented in Table 2 below.
- Phase I includes the initial introduction of OCFA-enriched poultry feed to the chickens and feeding until a steady state is seen in the fatty acid profile of the eggs. Then OCFA-enriched poultry feed is stopped to observe how quickly the OCFA levels in the eggs drop.
- Phase II begins with re-introduction of the OCFA-enriched poultry feed to the chickens and then again observing the impact on the fatty acid profile of the eggs.
- Test chickens were started on OCFA containing feed on day 0, and various fatty acids either rise of fall until a new level is reached.
- test chickens were switched to a standard commercially available feed (i.e. not containing OCFA rich Aurantiochytrium acetophilum HS399 biomass) and the fatty acid levels in the eggs started to fall; although the OCFA levels never reached their original low levels.
- Phase II is initiated, as the test chickens were again switched to the OCFA-enriched poultry feed and the levels of fatty acids responded, rising to a level of 4.6% DHA, 3.4% C17:0 and 2.6% C15:0 which are in line with the averages in Phase I of the experiment.
- FIG. 2 is a line graph showing the fatty acid composition (in percent TFA) of various fatty acids in the eggs of the control group chickens throughout the test duration.
- the raw data gathered during the experiment is presented in Table 3 below.
- DHA begins at ⁇ 0.8% and then drops as low as 0.5% but then ends at ⁇ 0.7%. This is just natural drift as a result of amount of feed intake the chickens have, error in analysis, and chicken health.
- OCFA-enriched poultry egg yields about 420 mg OCFA
- a typical two egg breakfast using two OCFA-enriched poultry eggs would give the consumer the recommended daily allowance of DHA (1 gram per day) and over 800 mg of OCFA per day, which is equivalent to getting the fatty acid nutrition out of almost 10 glasses of milk.
- the amount of OCFA collected in the yolk of the top 6 performing OCFA-enriched poultry eggs achieved a maximum average of 5.85% OCFA of the total fatty acid. This averages to about 445 mg OCFA per OCFA-enriched poultry egg. By comparison, this is equivalent to the amount of OCFA that a consumer would receive by drinking 5.4 glasses of 2% milk.
- a single OCFA-enriched poultry egg would provide the equivalent intake of OCFA to the total consumption of OCFA per capita availability per day based on USDA data (i.e.
- OCFA/day is how much a consumer would receive from total dairy products only (dairy products include milk, cheese, yogurt, etc.).
- the eggs of the control group chickens yielded an average of about 22 mg OCFA per egg. This is 20 times less than the maximum average of the OCFA-enriched poultry eggs. In other words, the amount of OCFA in the OCFA-enriched poultry eggs was 1,922% higher than the amount of OCFA in the eggs of the control group chickens that were only fed standard chicken feed.
- Tables 2-5 above and corresponding FIGS. 1-4 also show that the amount of OCFA that collected in the yolk of the OCFA-enriched poultry eggs during the steady state portion of Phase I (day 16 to day 55), was 5.58% OCFA of the total fatty acid. This averages to 408 mg OCFA per OCFA-enriched poultry egg with a standard deviation of 33 mg OCFA/OCFA-enriched poultry egg. By comparison, this is equivalent to the amount of OCFA that a consumer would receive by drinking 4.8 glasses of 2% milk.
- the eggs of the control group chickens yielded an average of about 22 mg OCFA per egg. This is 18.5 times less than the average of the OCFA-enriched poultry eggs. In other words, the amount of OCFA in the OCFA-enriched poultry eggs was 1,755% higher than the amount of OCFA in the eggs of the control group chickens that were only fed standard chicken feed.
- Phase II may be considered a replication of the results of Phase I.
- the eggs of the control group chickens yielded an average of about 22 mg OCFA per egg. This is 19.3 times less than the average of the OCFA-enriched poultry eggs. In other words, the amount of OCFA in the OCFA-enriched poultry eggs was 1,827% higher than the amount of OCFA in the eggs of the control group chickens that were only fed standard chicken feed.
- the DHA content of the OCFA-enriched poultry eggs was about 340 mg DHA per OCFA-enriched poultry egg, whereas the eggs of the control group chickens yielded only about 60 mg DHA per egg.
- the terms “may” and “may be” indicate a possibility of an occurrence within a set of circumstances; a possession of a specified property, characteristic or function; and/or qualify another verb by expressing one or more of an ability, capability, or possibility associated with the qualified verb. Accordingly, usage of “may” and “may be” indicates that a modified term is apparently appropriate, capable, or suitable for an indicated capacity, function, or usage, while taking into account that in some circumstances the modified term may sometimes not be appropriate, capable, or suitable. For example, in some circumstances an event or capacity can be expected, while in other circumstances the event or capacity cannot occur—this distinction is captured by the terms “may” and “may be.”
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Fodder In General (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Disclosed are compositions and methods for producing a poultry egg that is rich in odd-chain fatty acid (OCFA), particularly pentadecanoic acid (C15:0) and heptadecanoic (C17:0) acid. Poultry feed can be mixed with a compound (e.g. biomass or oil extract) that is produced from microalgae cultured to comprise elevated levels of OCFA. The OCFA-enriched poultry feed comprises an elevated level of OCFA and it can be fed to poultry that are laying eggs. As the OCFA-enriched feed is incorporated by the poultry, the resulting eggs comprise yolks that are rich in OCFA. The OCFA rich eggs can be consumed by humans as a dietary source of OCFA, to improve health.
Description
- The present application claims priority to and is a Continuation of U.S. patent application Ser. No. 16/577,384, filed on Sep. 20, 2019, which claims the benefit of U.S. Provisional Application No. 62/734,437, filed on Sep. 21, 2018, each of which is hereby incorporated by reference in its entirety for all purposes.
- This application relates generally to uses for microalgae biomass rich in odd-chain fatty acid and, more specifically, to compositions and methods for introduction of odd-chain fatty acids into poultry eggs.
- The citric acid cycle can govern the energy metabolism in aerobic organisms by producing 2 CO2, 3 NADH, 1 FADH2, and 1 ATP from the oxidation of acetyl-coA at every turn of the cycle. In addition, the cycle can provide precursors for biosynthesis of several amino acids, lipids, chlorophyll and other growth-related metabolites. The citric acid cycle is non-catalytic, which means that molecules used in biosynthesis are replenished so that the cycle can keep generating energy. Regardless of how much acetyl CoA is fed into the citric acid cycle, the cycle is able to produce merely a limited amount of citric acid intermediates. Anaplerotic substrates can be used to produce intermediates that are used to replenish the oxidative capacity of the citric acid cycle.
- Anaplerosis refers to the process of replenishing the citric acid cycle intermediates and restoring energy balance of the cell (metabolic homeostasis). Odd-chain fatty acids (OCFAs) can be considered anaplerotic because, along with acetate units, they can also release propionic acid which can enter the citric acid cycle through the methylmalonate pathway (OCFA catabolism). Typical dietary sources of OCFA are milk and butter, but they have only trace amounts (<2% total fatty acids, TFA) of pentadecanoic (C15:0) and heptadecanoic (C17:0) acid. Synthetically produced concentrated sources, such as tripentanoin and triheptanoin (e.g., oils containing C5:0 and C7:0), are not considered nutritional lipids. Further, current methods that involve the use of Yarrowia lipolytica to produce odd-chain fatty acids utilize genetic modification.
- Odd-chain fatty acids are known to have potential health benefits including, but not limited to, reduction of incidence of
type 2 diabetes, heart disease, and stroke as well as reducing incidence of neuro-degenerative diseases such as Alzheimer's disease and Lou Gehrig's disease. However, a primary constraint with OCFAs is the lack of their cost-effective availability. Thus, a need exists for a natural and cost-effective source of OCFAs, particularly C15:0 and C17:0 (two long odd-chain fatty acids), that may be incorporated into a commonly consumed food product. - Currently, poultry eggs that are rich in OCFA are not available. Eggs are already well-accepted as a source of protein and energy, and eaten by most people. Creating an egg with 10 times more (or more) OCFA than conventional eggs, using the techniques described herein, results in a product that is a quick, easy, readily available, and cost-effective way to introduce the healthy OCFA to a human diet. Further, the process of adding an OCFA rich biomass, or OCFA rich oil, to poultry feed is an easy and cost-effective way to produce the eggs that are rich in OCFA. The methods described here also detail how the biomass or oil rich in OCFA can be produced.
- This Summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key factors or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.
- Disclosed are compositions rich in odd-chain fatty acids, including pentadecanoic (C15:0) and heptadecanoic (C17:0) fatty acids, and products rich in pentadecanoic and heptadecanoic fatty acids derived from microalgae. In some embodiments, the total fatty acid profile of the composition includes a fraction comprising at least about sixty percent (60%) odd-chain fatty acids (OCFA), and about twenty-five (25%) docosahexaenoic acid (DHA).
- The microalgae and/or compositions rich in pentadecanoic and heptadecanoic acids may be used as a poultry feed or poultry feed ingredient. Methods and systems for increasing the production or concentration of pentadecanoic and heptadecanoic fatty acids from microalgae are also disclosed herein.
- Further, techniques are disclosed for increasing the concentration of OCFA in eggs, such as poultry eggs. For example, a biomass or oil rich in OCFA can be incorporated into poultry feed and fed to the egg-laying poultry. The OCFA in the feed fed to the poultry animals can result in an increase in the OCFA concentration in the fatty acid profile of the yolk of a resulting egg laid by the poultry animal.
- Additionally, techniques are disclosed for creating poultry feed that is rich in OCFA. For example, a poultry feed can be mixed with a compound derived from microalgae that is rich in OCFA. The resulting mixed poultry feed that is rich in OCFA can be fed to poultry to produce eggs that are rich in OCFA. For example, the OCFA eggs can be consumed by humans as a source of OCFA in their diet to improve health.
- In accordance with one or more embodiments of the present invention, an OCFA-enriched poultry feed having an elevated level of odd-chain fatty acid (OCFA) is disclosed. The OCFA-enriched poultry feed comprises: poultry feed; and a microalgae compound produced from culturing microalgae to produce microalgae with elevated levels of odd-chain fatty acid, the microalgae compound comprising one of a biomass and an extracted oil; and wherein the microalgae compound is mixed with the poultry feed at an inclusion rate greater than one percent of a resulting OCFA-enriched poultry feed.
- In accordance with one or more embodiments of the present invention, a poultry egg is disclosed. The poultry egg comprises an elevated level of OCFA, the elevated level comprising an amount greater than 3% percent of the fatty acid profile of the yolk, wherein the poultry egg was laid by a poultry animal having been fed an OCFA-enriched poultry feed composition comprising an effective amount of an OCFA-rich microalgae compound.
- In accordance with one or more embodiments of the present invention, a method for producing a poultry egg with an elevated amount of odd-chain fatty acid (OCFA) is disclosed. The method comprises: mixing a desired amount of OCFA-rich microalgae compound into poultry feed resulting in OCFA-enriched feed composition, the desired amount comprising greater than one percent of the OCFA-enriched feed; feeding the OCFA-enriched feed composition to poultry that lays eggs; and retrieving an egg produced by the poultry, the egg comprising an elevated amount of OCFA in the lipid profile of the yolk.
- To the accomplishment of the foregoing and related ends, the following description and annexed drawings set forth certain illustrative aspects and implementations. These are indicative of but a few of the various ways in which one or more aspects may be employed. Other aspects, advantages and novel features of the disclosure will become apparent from the following detailed description when considered in conjunction with the annexed drawings.
- The innovative concepts described herein may take physical form in certain parts and arrangements of parts, a preferred embodiment of which will be described in detail in the specification and illustrated in the accompanying drawings which form a part hereof, and wherein:
-
FIG. 1 is a line graph showing the fatty acid composition (in percent TFA) of various fatty acids in the eggs of the test group chickens; -
FIG. 2 is a line graph showing the fatty acid composition (in percent TFA) of various fatty acids in the eggs of the control group chickens; -
FIG. 3 is a line graph showing the mg of OCFA and DHA calculated for each egg of the test group chickens based on the compositional profile and the total fat content of each egg; -
FIG. 4 is a line graph showing the weight of both control group chicken eggs and test group chicken eggs over time; and -
FIG. 5 is a bar graph detailing the results of a blind taste test evaluation of the OCFA-enriched poultry eggs versus the eggs of the control group chickens. - The claimed subject matter is now described with reference to the drawings, wherein like reference numerals are generally used to refer to like elements throughout. In the following description, for purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the claimed subject matter. It may be evident, however, that the claimed subject matter may be practiced without these specific details. In other instances, structures and devices are shown in block diagram form in order to facilitate describing the claimed subject matter.
- With reference to the drawings, like reference numerals designate identical or corresponding parts throughout the several views. However, the inclusion of like elements in different views does not mean a given embodiment necessarily includes such elements or that all embodiments of the innovative concepts described herein include such elements. The examples and figures are illustrative only and not meant to limit the innovative concepts described herein, which is measured by the scope and spirit of the claims.
- The term “microalgae” refers to microscopic single cell organisms such as microalgae, cyanobacteria, algae, diatoms, dinoflagellates, freshwater organisms, marine organisms, or other similar single cell organisms capable of growth in phototrophic, mixotrophic, or heterotrophic culture conditions. The term “biomass” means a composition wherein substantially all of the components of the microalgae cells produced in the composition during culturing/growth remain present (e.g., in certain aspects of the invention at least about 90% of the cellular components, at least about 95% of the cellular components, or at least about 99% of the cellular components produced during growth/culturing remain present).
- In some embodiments, the microalgae biomass or extracts may be sourced from the class Labyrinthulomycetes to make a composition that may be used to increase odd-chain fatty acid concentrations in poultry eggs. The class Labyrinthulomycetes includes species of Schizochytrium and Aurantiochytrium.
- Non-limiting examples of microalgae genus and species that can be used in the compositions and methods of the claimed subject matter include: Aurantiochytrium sp., Aurantiochytrium acetophilum HS399, Chlorella sp., Haematococcus sp., Galdieria sp., Isochrysis sp., Micractinium sp., Porphyridium sp., Schizochytrium sp., Thraustochytrium sp., and Oblongichytrium sp.
- Taxonomic classification has been in flux for organisms in the genus Schizochytrium. Some organisms previously classified as Schizochytrium have been reclassified as Aurantiochytrium, Thraustochytrium, or Oblongichytrium. See Yokoyama et al. Taxonomic rearrangement of the genus Schizochytrium sensu lato based on morphology, chemotaxonomic characteristics, and 18S rRNA gene phylogeny (Thrausochytriaceae, Labyrinthulomycetes): emendation for Schizochytrium and erection of Aurantiochytrium and Oblongichytrium gen. nov. Mycoscience (2007) 48:199-211. Those of skill in the art will recognize that Schizochytrium, Aurantiochytrium, Thraustochytrium, and Oblongichytrium appear closely related in many taxonomic classification trees for microalgae, and strains and species may be re-classified from time to time. Thus, for references throughout the instant specification for Schizochytrium, it is recognized that microalgae strains in related taxonomic classifications with similar characteristics to Schizochytrium, such as Aurantiochytrium, would reasonably be expected to produce similar results.
- In some embodiments, the microalgae may be cultured in phototrophic, mixotrophic, or heterotrophic culture conditions in an aqueous culture medium. For embodiments where the microalgae is Aurantiochytrium acetophilum HS399, the Aurantiochytrium acetophilum HS399 is may be cultured in either mixotrophic or heterotrophic culture conditions in an aqueous culture medium. The organic carbon sources suitable for growing microalgae mixotrophically or heterotrophically may comprise: acetate, acetic acid, ammonium linoleate, arabinose, arginine, aspartic acid, butyric acid, cellulose, citric acid, ethanol, fructose, fatty acids, galactose, glucose, glycerol, glycine, lactic acid, lactose, maleic acid, maltose, mannose, methanol, molasses, peptone, plant based hydrolyzate, proline, propionic acid, ribose, sacchrose, partial or complete hydrolysates of starch, sucrose, tartaric, TCA-cycle organic acids, thin stillage, urea, industrial waste solutions, yeast extract, and combinations thereof. The organic carbon source may comprise any single source, combination of sources, and dilutions of single sources or combinations of sources. In some embodiments, the microalgae may be cultured in axenic conditions. In some embodiments, the microalgae may be cultured in non-axenic conditions.
- Anaplerosis refers to the replenishment of the citric acid intermediates that have been extracted by the cell for biosynthesis. Anaplerotic substrates, such as glucose, protein and odd-chain fatty acids, could be converted into citric acid intermediates to restore an energy imbalance of the cell. OCFAs are different from other anaplerotic substrates because they can undergo ketosis and cross the blood-brain barrier. Therefore, OCFAs have been associated with a decrease in metabolic disease risk, and their intake has been proposed for the treatment and prevention of various gene and brain disorders. The presence of OCFAs in diet is scarce and typically limited to ruminant fat (e.g., butter), which contains only trace amounts (<2% total fatty acid (TFA)) of pentadecanoic acid (C15:0) and heptadecanoic acid (17:0). Existing pharma OCFAs, such as tripentanoin and triheptanoin oils, are produced synthetically, and are made of fatty acids that are not typically present in a human diet. Alternatively, as described herein, a microbial process may be devised that can result in a natural algal oil comprising large (>50 TFA) quantities of dietary (C15:0 and C17:0) OCFAs.
- Typical anaplerotic substrates can include pyruvate (e.g., derived from carbohydrates), glutamine/glutamate (e.g., derived from protein) and precursors of propionyl-CoA, such as odd-chain fatty acids. Anaplerotic substrates can be used to restore energy balance in the mitochondria; and, there is a wide range of pathologies to which odd-chain fatty acids may provide benefits. As an example, in this aspect, odd-chain fatty acids have been experimentally used to treat: gene metabolic disorders, such as Glut1 deficiency, Fatty Acid Oxidation Disorder (FAOD), Pyruvate Carboxylase Deficiency, Carnitine Palmitoyltransferase II Deficiency, Huntington, Phenylketonuria, Adult Polyglucosan Body Disease (APBD), and Long-Chain Fat Oxidation Disorders; neural disorders, such as Epilepsy, Alzheimer's Disease, and Autism Spectrum Disorder (ASD); and circulatory system disorders, such as Ventricular Hypertrophy, and stroke.
- Dietary odd-chain fatty acids, pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0), also known as margaric acid, may be derived from ruminant fat (e.g., butter), and are thought to be likely derived from bacterial activity in the rumen of dairy producing animals. These OCFAs can be found in very small amounts (e.g., <2% total fatty acids (TFA)) in some dairy products (e.g., milk and butter). Pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) have also been found to be produced in the human gut, which may be triggered by dietary fiber intake, presumably supporting bacterial activity. Ref. 1. Because only trace amounts of odd-chain fatty acids (e.g., C15:0 and C17:0) are present in human diets, alternative sources (i.e. nutraceuticals, medical foods or therapeutics) can be used to significantly increase the intake of this type of nutrient.
- Currently, merely limited amounts of odd-chain fatty acids (e.g., C15:0 and C17:0) are readily available from known natural, dietary sources, such as ruminant fat. In one aspect, compositions can be created that comprise a higher concentration than current sources of odd-chain fatty acids such as pentadecanoic and heptadecanoic fatty acids. Further, in one aspect, a method can be devised for efficient and affective generation of such fatty acids from a newly derived source.
- Microalgae can produce a variety of fatty acids, the composition of which can vary among different strains. As an example, thraustochytrids can accumulate lipids up to eighty-five (85%) of their dry weight; and, amongst the oleaginous microorganisms, they may be one of the fastest growing. Further, these organisms can be adapted to fermentation conditions (e.g., low shear sensitivity, high osmotolerance) for use in industrial production of microbe-based oils. For example, Aurantiochytrium acetophilum HS399 (hereinafter, “HS399”) is a thraustochytrid that can produce an oil containing palmitic acid (e.g., 45% total fatty acids (TFA)), n-6 docosapentaenoic acid (e.g., 8% TFA), and n-3 docosahexaenoic (e.g., 40% TFA) as the main fatty acids, with other fatty acids present in trace amounts. Pursuant to the requirements of the Budapest Treaty, a live culture of the Aurantiochytrium acetophilum HS399 microalgae strain described herein was deposited on Sep. 12, 2019 at National Center for Marine Algae and Microbiota (NCMA), located at 60 Bigelow Drive, East Boothbay, Me. 04544, USA and received accession number 201909001.
- The trace fatty acids of HS399 can include pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) (e.g., at <0.3% TFA). The trace fatty acids, including these two identified fatty acids, are typically ignored in the lipid profile reports for these organisms. Odd-chain fatty acids, including pentadecanoic acid and heptadecanoic acid, are fatty acids that contain an odd number of carbon atoms in the structure. Pentadecanoic acid and heptadecanoic acid are both considered long chain fatty acids because they both contain more than 12 carbon atoms. OCFAs are typically related to bacterial activity (i.e. propionic acid bacteria), and are less likely to be present in algae or plants. Ref. 2
- Aurantiochytrium acetophilum HS399 naturally contains trace amounts of C15:0. The presence of trace amounts in Aurantiochytrium acetophilum HS399 suggests that the pathway responsible for the synthesis of OCFA may be present in Aurantiochytrium acetophilum HS399. Because of the composition of their fatty acid profile, and their ability to be grown rapidly, microalgae such as Aurantiochytrium acetophilum HS399 provide an attractive source of odd-chain fatty acids by generating odd-chain fatty acids in a more concentrated manner than other known natural sources, such as milk fat (e.g., providing a more cost effective and efficient source of OCFA). As an example, a benefit of using microalgae in place of butter and other ruminant fat is the higher concentration of OCFA found in them. In addition, as another example benefit, some microalgae oil lacks residues of phytol or phytanic acid that are often present in ruminant fat. Consumption of phytol or phytanic acid can lead to health concerns in some individuals.
- Techniques have been devised that provide for an increased production of naturally occurring odd-chain fatty acids from microalgae. The cultivated microalgae and/or isolated composition may be used individually as products or as an ingredient in a variety of products. As an example, microalgae such as Aurantiochytrium acetophilum HS399 can be cultivated to produce a desirable fatty acid profile comprising OCFAs, which may be isolated through various extraction processes. In this example, the isolated oil containing the OCFAs may comprise a composition rich in OCFAs, such as pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0). However, in one implementation, the microalgae may be cultivated using an improved method that includes the presence of a complex media, which can promote increased production of the OCFAs.
- In one or more embodiments, propionic acid (e.g., and or one or more propionates, such as the anion, salts, and/or esters of propionic acid) may be used as a precursor for production of OCFA. In this implementation, for example, it is likely that Aurantiochytrium acetophilum HS399 can incorporate propionic acid in its lipid generation pathway, resulting in the production of OCFAs.
- Generally, fatty acid synthesis in microalgae consists of a lipid synthesis pathway involving acetyl CoA, and some metabolic cycles. As an example, acetyl-coenzyme A (CoA) is a universal carbon donor for fatty acid biosynthesis. Acetyl-CoA can be supplied be multiple paths, from various origins, and then subsequently metabolized into malonyl-acyl carrier protein (ACP) (or Malonyl CoA) by sequential reactions (e.g., utilizing acetyl-CoA carboxylase (ACCase) in carboxylation of A CoA). In this example, fatty acid synthesis follows, resulting in the production of the fatty acids.
- The genome of Aurantiochytrium acetophilum HS399 suggests that saturated fats are synthetized through the Fatty Acid Synthase (FAS) pathway that uses acetyl-coA as a building block for the fatty acid elongation. The production of even chain fatty acids uses a malonyl-ACP as a substrate for elongation. As described herein, in one implementation, when propionic acid is present the acyl carrier protein (ACP) cleaves to methylmalonyl instead of malonyl, resulting in the FAS producing of odd-chain fatty acids instead of even chain fatty acids. Palmitic acid (C16:0) is typically the primary even chain fatty acid in HS399, while the primary OCFAs is typically pentadecaenoic (C15:0) instead of heptadecanoic acid (17:0). In this implementation, fatty acid synthesis of palmitic acid (C16:0) undergoes 6 consecutive elongation cycles, while the (C15:0) OCFA undergoes only 5 elongation cycles before the fatty acid is liberated from the acyl carrier protein. In one implementation, a microbial process may be used to culture microalgae, which can result in a microalgae biomass and/or microalgae oil comprising large (>50 TFA) quantities of dietary OCFA (C15:0 and C17:0). Such quantities of dietary OCFA (C15:0 and C17:0) are significantly higher than what is found in the naturally occurring microalgae.
- In addition to the common and traditional use of propionic acid as an antimicrobial agent that kills algae, as described herein, techniques have been devised for propionic acid to be used to facilitate the growth of microalgae, and/or to increase OCFA production in the microalgae. In one implementation, in this aspect, propionic acid (e.g., and/or propionates) can be introduced into an algal bioprocess using a fed-batch approach, while reducing the potential toxic effects on the algae. According to one or more embodiments, microalgae such as Aurantiochytrium acetophilum HS399 can be added to the culture medium. Propionic acid may then be added to the culture medium comprising the Aurantiochytrium acetophilum HS399 in a batch, continuous feed, or fed-batch process, and cultured in a bioreactor with the culture medium.
- In one embodiment, the Aurantiochytrium acetophilum HS399 cells were cultured in a two-stage axenic process which first feeds DE95 (which comprises about 95% dextrose) as a growth carbon source and then, after a specified period of time, feeds propionate to the microalgae, which causes the microalgae to produce OCFA as a part of its fatty acid profile. The “two-stage axenic process” refers to the first stage wherein propionate is not fed to the microalgae and the second stage wherein propionate is fed to the microalgae. The propionic acid can be added at a ratio of at least 0.05 g of propionic acid per gram of Aurantiochytrium acetophilum HS399 biomass, in order to accumulate elevated amounts of OCFA. In one embodiment, 0.15 g of propionic acid is added per gram of Aurantiochytrium acetophilum HS399 biomass, in order to accumulate OCFA above 50% TFA. In another implementation, the propionic acid can be added at a rate of above zero and up to about 3 g/L per day. In one implementation, the propionic acid can be added at a rate of above zero and up to about 3 g/L per day for three days, resulting in a total propionic acid addition of about 9 g/L. In one embodiment, adding the propionate can comprise adding the propionate in a fed-batch approach into the culture medium. In one embodiment, adding the propionate can comprise adjusting the propionate fed to produce OCFAs in a range of 5 and 70% TFAs. Optionally, anaplerotic oil containing concentrated amounts of OCFA can be extracted from the Aurantiochytrium acetophilum HS399. In one embodiment, anaplerotic oil can be produced from the cultured microalgae, wherein at least five percent of the total fatty acids (TFA) of the anaplerotic oil are OCFAs, and OCFAs make up at least one percent cell dry weight (CDW) of the anaplerotic oil. Although the above method is disclosed in detail, it should be clearly understood that substantial benefit may still be obtained from using alternative culturing methods that would cause the microalgae to produce elevated levels of OCFA as a part of its fatty acid profile such as, but not limited to, the methods discussed in International Application Number PCT/US2018/067104, Taberna et al., which is incorporated herein in full by reference.
- After the Aurantiochytrium acetophilum HS399 cells achieved the desired OCFA profile, they were harvested, washed (i.e. diluted with water in a ratio of 2:1 and centrifuged in order to remove dissolved material and small particles), and then dried with NATUROX® antioxidant thus forming the Aurantiochytrium acetophilum HS399 biomass used in the experiments described herein. It should be clearly understood that other variations of the Aurantiochytrium acetophilum HS399 biomass microalgae, including variations in the microalgae strains, microalgae growth or processing methods, or variations in the stabilizers, may be used and may achieve similar results.
- The anaplerotic oil produced by microalgae can contain a substantial amount of DHA, which is a valuable nutraceutical. For example, DHA (docosahexaenoic acid) is a fatty acid that is commonly found in the meat of cold-water fish (e.g., tuna, salmon, cod, etc.). DHA has been found to early brain development in infants, and may improve the vision and cognitive function development. Further, DHA has been used for treating
type 2 diabetes, coronary artery disease (CAD), dementia, depression, and attention deficit-hyperactivity disorder (ADHD), as well as improving vision and cognitive function in adults. Additionally, DHA can be converted into eicosapentaenoic acid (EPA) in the body, which is used in the prevention and reversal of heart disease, stabilizing heart rhythm, asthma, cancer, painful menstrual periods, hay fever, lung diseases, systemic lupus erythematosus (SLE), and certain kidney diseases. Both EPA and DHA have been used in combination to treat high cholesterol, high blood pressure, psoriasis, Raynaud's syndrome, rheumatoid arthritis, bipolar disorder, certain inflammations of the digestive system (ulcerative colitis), and to prevent migraine headaches in teenagers. In one or more embodiments, the anaplerotic oils produced by Aurantiochytrium acetophilum HS399 may contain OCFAs C15:0 and C17:0 at 60% TFA and DHA at about 25% TFA. - In one implementation, the propionate fed approach can cause some growth inhibition in the microalgae, but may not result in a complete culture loss of the microalgae batch. In this implementation, the fed-batch approach may achieve similar cell densities and overall lipid accumulation as a similar control batch with no propionic acid fed, with merely a one-day difference. As one example, propionic acid may be fed into the algal culture batch on demand (e.g., automatically fed using a pH-auxostat fed batch system). As another example, propionic acid may be fed into the microalgal batch along with a carbon source (e.g., glucose, glycerol or acetate) at a ratio below 0.1 of weight to weight (w/w) of propionic acid to carbon source (propionic acid/carbon source ratio). In another example, propionic acid may be fed along with the carbon source at a ratio below 0.05 w/w propionic acid to carbon source, to mitigate or avoid accumulation of propionate in the culture media. In one example, propionic acid may be fed into a culture at a culture pH higher than 5. A low pH increases the toxicity of propionic acid making it more difficult to balance the window between propionate incorporation and growth inhibition. Specific details and experiments regarding the methods for increasing odd-chain fatty acid production in microbials such as microalgae (e.g. Aurantiochytrium acetophilum HS399) are provided in International Application Number PCT/US2018/067104, Taberna et al., which is incorporated herein in full by reference.
- Techniques and systems were devised to incorporate OCFAs (as well as DHA) found in the resulting microalgae biomass and/or microalgal oil into poultry eggs. As an example, the biomass rich in OCFA, and/or the oil rich in OCFA, were processed into poultry feed and fed to layer chickens. In this example, the enriched feed can be fed to poultry animals, such as chickens, resulting in the incorporation of OCFA in the compositional profile of the poultry egg. In this way, for example, the enriched eggs can be a vehicle for delivering the OCFA to human consumers. As a result, a healthier egg can be created which can provide positive benefits to the cardiometabolic health (e.g., heart disease, diabetes, and stroke) of the human consumers, at a lower cost than typical pharmaceutical or nutraceutical treatments.
- In one aspect, a biomass of microalgae rich in OCFA can be fed to poultry animal, such as chickens, directly or as a processed feed. In one implementation, in this aspect, the biomass can be fed directly to the poultry, for example, as a supplement to other feed. In another implementation, the biomass can be processed into a pelletized form and fed to the poultry, for example, as a supplement to other feed. In another implementation, the biomass can be combined with typical poultry feed, and the combination can be processed into a pelletized form as poultry feed.
- In one implementation, the increased amount of OCFA in whole biomass can be mixed with standard poultry food, for example, in the range of 1.5-6.3% inclusion of the biomass into the feed. In this implementation, the mixed feed can then be fed to the poultry (e.g., chickens). The poultry can eat the food, for example, for chickens at the standard 0.2-0.25 lbs. per day of total food intake. In this implementation, the OCFA can be incorporated into the developing egg, and will appear as part of the fatty acid compositional profile of the yolk of the resulting poultry egg.
- In another implementation, the whole biomass can be mixed with standard poultry food, for example, in the range of 1.5-6.3% inclusion of the biomass into the feed. In this implementation, the mixed feed can then be processed into pellets, which include the biomass rich in OCFA. Further, the pelletized mixed feed can be fed to the poultry, in a similar manner as above.
- In another implementation, oil derived from the biomass, such as algal oil, comprising the elevated concentration of OCFA, can be mixed with standard poultry food, for example, in the range that may be the same as that of the whole biomass (e.g. 1.5-6.3% inclusion) or may be less than that of the whole biomass (e.g., 0.5% to 4% inclusion of the oil into the feed). In this implementation, the oil-feed mix can be fed to the poultry. In another implementation, the oil-feed mix can be processed into pellets, and fed to the poultry.
- The resulting egg produced by the poultry, using the techniques described herein, may include an increase in OCFA over eggs produced by poultry that are not subjected to the treated feed. For example, the pathway for digestion of fat by a chicken results in approximately 50 to 65% of the fat intake directed to produce egg yolks. That is, for example, whatever fat the chicken intakes can end up in a resulting egg yolk. Further, some of the OCFA eaten by poultry may not end up as OCFA in the resulting yolk. For example, some fatty acids may be metabolized for energy, stored, or incorporated in muscle. In one implementation, the composition impact on the egg can be in the range of about 1% to 6.2% of total OCFA (C15:0 plus C17:0), of the total fatty acid profile of the egg.
- In accordance with one or more embodiments of the present invention, an OCFA-enriched poultry feed was created. To prepare the OCFA enriched feed, a standard commercially available chicken feed (e.g. PETCLUB Layer Crumbles) was provided and used as the base feed. A 2.6% inclusion rate of OCFA rich Aurantiochytrium acetophilum HS399 biomass was combined with the standard conventional feed, thus creating the OCFA-enriched poultry feed. This was accomplished by mixing the correct inclusion rate of OCFA rich Aurantiochytrium acetophilum HS399 biomass with the base feed evenly, and then forming the new composition into pellets for the subject chickens to consume. Although a 2.6% inclusion rate of OCFA-rich Aurantiochytrium acetophilum HS399 biomass was used in the experiment, it should be clearly understood that substantial benefit would be obtained by using an alternative rate such as 1.5-6.3% of inclusion of OCFA-rich Aurantiochytrium acetophilum HS399 biomass in the feed, which would likely result in about 250 mg to 1,000 mg of OCFA per egg. The % inclusion of the OCFA-rich Aurantiochytrium acetophilum HS399 biomass (or OCFA-rich Aurantiochytrium acetophilum HS399 oil) may be increased or decreased depending upon how much OCFA is desired to be present in the resulting egg yolk.
- It should be noted that this is merely one example from an initial study of the effectiveness of the techniques described herein. It is expected that the amount of OCFA can be even higher when fed to poultry over an extended period of time, for example, two to three times higher, or more. It should be clearly understood that although OCFA rich Aurantiochytrium acetophilum HS399 biomass was used in this experiment to create the OCFA-enriched poultry feed, the same results would still be obtained if the OCFA rich oil was extracted from the OCFA rich Aurantiochytrium acetophilum HS399 biomass and the extracted OCFA rich oil was mixed with the standard conventional feed. Of note, C15:0 and C17:0 fatty acids are the long odd-chain fatty acids identified in this example, as italicized and bolded below.
- The OCFA rich Aurantiochytrium acetophilum HS399 biomass used for this experiment had an elevated amount of C:15 and C:17, in particular. Table 1 below shows a comparison of the fatty acid profiles of the standard conventional feed alone versus the OCFA-enriched poultry feed. With respect to C15:0 and C17:0 in particular, the OCFA-enriched poultry feed contained 0.88% TFA of C15:0 while the standard conventional feed contained absolutely no C15:0 OCFA; furthermore, the OCFA-enriched poultry feed contained 0.84% TFA of C17:0 OCFA while the standard conventional feed only contained 0.12% TFA of C17:0 OCFA.
-
TABLE 1 Conventional Feed vs. OCFA treated feed Fatty Acid Conventional Feed OCFA Enriched Feed C14:0 0.38% 0.22% C15:0 0.0 0.88% C16:0 24.4% 25.4% C16:1 1.53% 2.22% C17:0 0.12% 0.84% C18:0 9.21% 8.78% C18:1 40.07% 34.7% C18:2 18.44% 20.35% C18:3 0.56% 0.66% C20:4 0.0 0.0 C22:5n6 1.07% 0.99% C22:6 (DHA) 0.83% 1.57% % TFA of Biomass 50.3 52.1% Protein % of Biomass 38 36 Total OCFA 0.12% 1.72% - Analytical verification was used to ensure that the targeted composition was met for the OCFA-enriched poultry feed pellets. Pellets were chosen as the form of the OCFA-enriched poultry feed because the chickens would not be able to differentiate between the OCFA-enriched poultry feed versus their typical base feed, which was also in pelletized form. This helped to ensure the chickens' consumption of the OCFA-enriched poultry feed. Additionally, chickens tend to waste less feed when it is in pelletized form, again helping to ensure that they are consuming the OCFA-enriched poultry feed. The base feed for the control chickens is simply pressed into pellets with no additional components added and fed as noted in the treatment description further below.
- For this study, 4-6 chickens were established as the control group. The control group was fed the standard commercially available base feed. The control group chickens were allowed to eat freely as they desired, which was at a rate of about 0.25 lbs/day/chicken. Another group of 4-6 chickens made up the test group. The test group was fed with the OCFA-enriched poultry feed, with contained the 2.6% inclusion of OCFA rich Aurantiochytrium acetophilum HS399 biomass. The test group chickens were also allowed to eat freely as they desired, which was also at a rate of about 0.25 lbs/day/chicken. Eggs from both the control group and the test group were collected either daily or every other day and were delivered for analysis twice per week on Mondays and Thursdays.
- For preparation of the samples, egg yolks were separated from the egg whites and only the yolks were analyzed. The eggs were mixed at 3-6 eggs per every 2-3 day period, freeze dried, and then submitted for analysis.
-
FIG. 1 is a line graph showing the fatty acid composition (in percent TFA) of various fatty acids in the eggs of the test group chickens throughout the test duration. The raw data gathered during the experiment is presented in Table 2 below. -
TABLE 2 Percentage of TFA of Various Fatty Acids in Test Group Eggs C22:5n6 C22:6n3 Day C15:0 C16:0 C17:0 C18:1 (DPA) (DHA) 0 0.00 24.40 0.35 40.07 1.07 0.83 4 0.00 25.93 0.33 36.05 0.93 0.76 7 0.88 25.40 0.84 34.70 1.00 1.52 10 2.44 24.79 2.23 31.95 0.63 3.65 14 2.91 24.10 2.74 31.47 0.40 4.52 16 2.86 23.30 2.93 32.10 0.37 4.92 20 2.66 24.13 2.79 32.95 0.35 4.66 23 2.77 24.10 2.89 32.90 0.41 4.57 27 2.59 26.10 2.55 31.99 0.35 4.34 30 2.71 24.26 2.98 32.73 0.39 4.69 34 2.76 25.25 2.83 31.40 0.31 4.52 37 2.787 23.9377 2.921 30.783 0.35 4.64 41 2.822 23.724 2.882 30.671 0.39 5.01 44 2.955 22.807 3.18 30.729 0.37 5.14 48 2.627 24.025 2.889 31.315 0.48 5.48 51 2.59 23.49 2.90 32.13 0.36 5.02 55 2.35 23.98 2.69 32.53 0.31 4.54 58 1.56 23.92 1.88 34.07 0.33 3.57 62 0.554 25.268 0.888 36.898 0 2.036 65 0.35 26.091 0.575 36.973 0 1.6 69 0.379 25.701 0.631 37.6228 0 1.575 72 0.788 25.371 1.088 36.781 0 2.1 76 1.361 24.697 1.79 35.866 0 3.054 79 1.876 24.09 2.369 34.635 0 3.554 83 2.6433 21.7742 3.4425 32.1067 0.3524 4.594 86 2.419 22.422 3.33605 33.39 0.24875 4.0553 90 2.502 23.0734 2.865 32.5869 0.33351 3.9364 93 2.255 23.9631 2.7715 34.3698 0.2832 3.9036 97 2.6483 23.458 3.0494 33.4611 0.3486 4.3577 - For this experiment, OCFA-enriched poultry feed was utilized in two separate phases of the experiment. Phase I includes the initial introduction of OCFA-enriched poultry feed to the chickens and feeding until a steady state is seen in the fatty acid profile of the eggs. Then OCFA-enriched poultry feed is stopped to observe how quickly the OCFA levels in the eggs drop. Phase II begins with re-introduction of the OCFA-enriched poultry feed to the chickens and then again observing the impact on the fatty acid profile of the eggs.
- Test chickens were started on OCFA containing feed on
day 0, and various fatty acids either rise of fall until a new level is reached. Onday 50, test chickens were switched to a standard commercially available feed (i.e. not containing OCFA rich Aurantiochytrium acetophilum HS399 biomass) and the fatty acid levels in the eggs started to fall; although the OCFA levels never reached their original low levels. Onday 66 Phase II is initiated, as the test chickens were again switched to the OCFA-enriched poultry feed and the levels of fatty acids responded, rising to a level of 4.6% DHA, 3.4% C17:0 and 2.6% C15:0 which are in line with the averages in Phase I of the experiment. -
FIG. 2 is a line graph showing the fatty acid composition (in percent TFA) of various fatty acids in the eggs of the control group chickens throughout the test duration. The raw data gathered during the experiment is presented in Table 3 below. -
TABLE 3 Percentage of TFA of Various Fatty Acids in Control Group Eggs C22:5n6 C22:6 Day C15:0 C16:0 C17:0 C18:1 C18:3 (DPA) (DHA) 0 0 24.4 0.35 40.07 0.56 1.07 0.83 10 0 26.063 0.32 38.421 0.49 0.753 0.688 16 0.00 25.97 0.00 37.61 0.70 0.574076 0.714121 20 0 28.28979 0 42.4551 0.3698 0.412054 0.512666 30 0 26.61415 0 39.24438 0.585817 0.521864 0.693454 37 0 25.6591 0.2406 37.737 0.6327 0.5253 0.7426 44 0 25.4615 0.2431 38.1539 0.6219 0.5377 0.8605 65 0 25.149 0.3259 39.983 0.6041 0 0.8226 72 0 26.0368 0.2927 41.2339 0.4707 0 0.8095 79 0 25.251 0.2982 41.1259 0.5202 0.4817 0.6428 86 0 24.9952 0.23465 41.1792 0.5629 0.361 0.681 - As shown, there are no trends of significance. For example, DHA begins at ˜0.8% and then drops as low as 0.5% but then ends at ˜0.7%. This is just natural drift as a result of amount of feed intake the chickens have, error in analysis, and chicken health.
- The mg of OCFA and DHA were calculated for each egg of the test group chickens based on the compositional profile and the total fat content of each egg. These results are shown graphically in
FIG. 3 and the raw data from this experiment is shown in Table 4 below. -
TABLE 4 Total mg of Certain Fatty Acids Per Egg C22:5n6 C22:6 Day C15:0 C16:1 C17:0 C18:3 C20:3 n3 (DPA) (DHA) 0 0.0 115.4 26.4 42.3 0.0 80.7 62.6 4 0.0 186.6 27.8 52.2 218.4 77.1 63.5 7 61.1 154.1 58.3 45.8 174.9 69.4 105.5 10 188.1 144.4 172.4 56.5 148.8 48.3 281.3 14 205.4 121.4 193.4 55.1 28.2 319.0 16 190.9 108.2 196.1 47.9 93.2 24.9 329.1 20 182.2 130.5 191.0 44.2 97.0 23.7 318.6 23 175.9 125.5 183.7 42.3 91.1 25.7 290.5 27 194.9 194.8 191.9 48.9 94.5 26.0 325.7 30 196.9 142.6 216.7 46.9 93.5 28.3 340.6 34 207.8 165.3 213.4 51.6 92.9 23.5 340.5 37 230.2 161.9 241.3 59.8 95.7 29.0 383.6 41 191.0 129.0 195.0 48.0 86.7 26.5 338.8 44 209.7 111.4 225.7 49.3 86.4 26.5 364.9 48 189.2 129.9 208.1 44.2 89.7 34.4 394.5 51 202.1 139.7 226.2 50.7 91.7 27.8 391.5 55 206.7 170.8 236.0 56.6 105.3 27.6 398.3 58 126.8 156.6 152.9 54.2 127.2 26.7 290.0 62 45.0 223.3 72.1 44.1 147.5 0.0 165.3 65 27.7 241.6 45.6 44.7 147.9 0.0 126.8 69 32.7 242.9 54.4 47.0 176.2 0.0 135.8 72 62.2 217.5 85.9 40.3 161.7 0.0 165.7 76 101.1 196.2 133.0 37.9 139.3 0.0 226.9 79 137.9 176.2 174.2 40.1 124.2 0.0 261.3 83 203.8 133.8 265.4 50.0 115.9 27.2 354.2 86 206.9 150.3 285.3 49.3 131.5 21.3 346.8 90 172.3 150.7 197.3 41.0 108.4 23.0 271.1 93 165.8 160.1 203.8 40.4 113.3 21.3 293.8 97 194.7 166.6 224.2 45.1 102.6 22.8 285.3 - As shown, the results are very similar to the TFA profiles noted in
FIG. 1 and corresponding Table 2. For example, the total fatty acid content of Phase I and Phase II is again very similar at their steady state values. Additionally, it is again observed that some fatty acids, such as C16:1, have an inverse relationship to the content of OCFA. However, this representation makes it easy to observe the amounts of fatty acid that one would receive by consuming an egg laid by a chicken that consumed OCFA-enriched poultry feed (i.e. an OCFA-enriched poultry egg). For example, where one OCFA-enriched poultry egg yields about 420 mg OCFA, a typical two egg breakfast using two OCFA-enriched poultry eggs would give the consumer the recommended daily allowance of DHA (1 gram per day) and over 800 mg of OCFA per day, which is equivalent to getting the fatty acid nutrition out of almost 10 glasses of milk. - The weight of both control and test eggs were collected over time, and are represented in
FIG. 4 and Table 5 below. -
TABLE 5 Egg Weight Over Time Control Control Control Control Egg Yolk White Shell Day weight (g) weight (g) weight (g) weight (g) 0 15.00 25.00 4 7 10 14 16 52.8 17.57 29.50 5.71 20 53.4 20.50 29.00 30 55.9 18.30 31.20 6.40 37 55.9 16.80 33.40 5.70 44 54.7 17.30 30.50 7.00 51 61.8 18.20 36.00 7.60 58 54.7 18.30 31.90 7.20 65 56.4 18.10 31.40 6.90 72 59.7 18.20 34.00 7.50 79 58.6 16.60 34.70 7.40 86 58.1 19.90 31.90 6.30 93 55.7 17.50 30.70 7.50 - As shown, there are no significant trends of weight gain, or weight loss over time in either the control group chicken eggs or in the test group chicken eggs. There does not appear to be an impact on the overall weight of the egg from OCFA-enriched poultry feed consumption. There is a slight upward trend in the test group chicken egg total weight, and an even more slight upward trend in the control group chicken egg total weight. This trend is not related to the consumption of OCFA-enriched poultry feed, as both control group chicken eggs and test group chicken eggs have this slight trend. This non-significant trend can be attributed to the maturing of the chickens themselves. The chickens used in the study were younger chickens, and as they matured the eggs they laid gained weight. The control group chickens were older than the test group chickens by about 6 months. A typical egg is 55-62 g, and both the test group chicken eggs and control group chicken eggs were trending in this slightly upward direction. There was also no observable effect from OCFA-enriched poultry feed consumption on the chicken appearance or health.
- As shown in Tables 2-5 above and corresponding
FIGS. 1-4 , the amount of OCFA collected in the yolk of the top 6 performing OCFA-enriched poultry eggs achieved a maximum average of 5.85% OCFA of the total fatty acid. This averages to about 445 mg OCFA per OCFA-enriched poultry egg. By comparison, this is equivalent to the amount of OCFA that a consumer would receive by drinking 5.4 glasses of 2% milk. By further comparison, a single OCFA-enriched poultry egg would provide the equivalent intake of OCFA to the total consumption of OCFA per capita availability per day based on USDA data (i.e. if you take the USDA dairy intake per capita in the US and factor in how much OCFA is in the dairy, then about 0.48 g OCFA/day is how much a consumer would receive from total dairy products only (dairy products include milk, cheese, yogurt, etc.). The eggs of the control group chickens yielded an average of about 22 mg OCFA per egg. This is 20 times less than the maximum average of the OCFA-enriched poultry eggs. In other words, the amount of OCFA in the OCFA-enriched poultry eggs was 1,922% higher than the amount of OCFA in the eggs of the control group chickens that were only fed standard chicken feed. - Tables 2-5 above and corresponding
FIGS. 1-4 also show that the amount of OCFA that collected in the yolk of the OCFA-enriched poultry eggs during the steady state portion of Phase I (day 16 to day 55), was 5.58% OCFA of the total fatty acid. This averages to 408 mg OCFA per OCFA-enriched poultry egg with a standard deviation of 33 mg OCFA/OCFA-enriched poultry egg. By comparison, this is equivalent to the amount of OCFA that a consumer would receive by drinking 4.8 glasses of 2% milk. The eggs of the control group chickens yielded an average of about 22 mg OCFA per egg. This is 18.5 times less than the average of the OCFA-enriched poultry eggs. In other words, the amount of OCFA in the OCFA-enriched poultry eggs was 1,755% higher than the amount of OCFA in the eggs of the control group chickens that were only fed standard chicken feed. - It is also shown in Tables 2-5 above and corresponding
FIGS. 1-4 that the amount of OCFA that collected in the yolk of the OCFA-enriched poultry eggs during the steady state portion of Phase II (day 83 to day 97), was 5.59% OCFA of the total fatty acid. This averages to 424 mg OCFA per OCFA-enriched poultry egg with a standard deviation of 56 mg OCFA/OCFA-enriched poultry egg. The layer chickens were very near molting by the end of the experiment and this may have contributed to the higher standard deviation of the data. By comparison, this is equivalent to the amount of OCFA that a consumer would receive by drinking 5.0 glasses of 2% milk. This value of 424 mg OCFA per OCFA-enriched poultry egg is <4% higher than that of Phase I, and considered to be well within the experimental error of the experiment. Therefore, Phase II may be considered a replication of the results of Phase I. The eggs of the control group chickens yielded an average of about 22 mg OCFA per egg. This is 19.3 times less than the average of the OCFA-enriched poultry eggs. In other words, the amount of OCFA in the OCFA-enriched poultry eggs was 1,827% higher than the amount of OCFA in the eggs of the control group chickens that were only fed standard chicken feed. - As also shown in Tables 2-5 above and corresponding
FIGS. 1-4 , the DHA content of the OCFA-enriched poultry eggs was about 340 mg DHA per OCFA-enriched poultry egg, whereas the eggs of the control group chickens yielded only about 60 mg DHA per egg. - An in-house taste test was performed using both the control group chicken eggs (“farm fresh” eggs), and the test group chicken eggs (OCFA-enriched poultry egg). The experiment was of interest because the DHA, which is contained in the test group chicken eggs along with the OCFA, can generate a ‘fishy’ or off taste. In particular, DHA can generate this off taste when it becomes oxidized, and as oxidation is exacerbated by heating, it was a question if cooking the eggs would cause the eggs to taste like fish, which clearly would not be a benefit for the general appeal of the eggs to a consumer.
- In a blind study, ten in-house participants evaluated both the control group chicken eggs and the test group chicken eggs (containing the OCFA and DHA). Both eggs were prepared by simply cooking them “over easy” in butter on an electric skillet with no additional salt, pepper or any other component added. As observed in the image below, there is no difference in appearance of the OCFA-enriched poultry eggs or farm fresh egg as they are cooking on the skillet surface.
- The results are shown in
FIG. 5 . The most important question was of course whether any hint of ‘fishy’ or off taste could be detected in the OCFA-enriched poultry eggs. None of the 10 participants could find any taste of fish or off taste in either of the eggs. The next most important determination was if the OCFA or DHA in the test group chicken eggs would impact the taste such that they could be differentiated from the control group chicken eggs. About 70% of the participants preferred the OCFA-enriched poultry eggs or could not tell a difference in the two eggs. Thirty percent of the participants were able to pick out the OCFA-enriched poultry eggs, and each reported that the control egg tasted “more salty” than the OCFA-enriched poultry eggs. As they were prepared in identical methods, this is an unexpected observation. A final interesting observation was that several participants thought both eggs were clearly better than anything they purchase at the conventional shopping market. - All references, including publications, patent applications, and patents, cited herein, are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law), regardless of any separately provided incorporation of particular documents made elsewhere herein.
- Unless otherwise stated, all exact values provided herein are representative of corresponding approximate values (e.g., all exact exemplary values provided with respect to a particular factor or measurement can be considered to also provide a corresponding approximate measurement, modified by “about,” where appropriate). All provided ranges of values are intended to include the end points of the ranges, as well as values between the end points.
- The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability, and/or enforceability of such patent documents.
- The inventive concepts described herein include all modifications and equivalents of the subject matter recited in the claims and/or aspects appended hereto as permitted by applicable law.
- The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability, and/or enforceability of such patent documents.
- The inventive concepts described herein include all modifications and equivalents of the subject matter recited in the claims and/or aspects appended hereto as permitted by applicable law.
- Although a particular feature of the disclosed techniques and systems may have been disclosed with respect to only one of several implementations, such feature may be combined with one or more other features of the other implementations as may be desired and advantageous for any given or particular application. Also, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in the detailed description and/or in the claims, such terms are intended to be inclusive in a manner similar to the term “comprising.”
- This written description uses examples to disclose the innovative concepts described herein, including the best mode, and also to enable one of ordinary skill in the art to practice the innovative concepts described herein, including making and using any devices or systems and performing any incorporated methods. The patentable scope of the innovative concept described herein is defined by the claims, and may include other examples that occur to those skilled in the art. Such other examples are intended to be within the scope of the claims if they have structural elements that are not different from the literal language of the claims, or if they include equivalent structural elements with insubstantial differences from the literal language of the claims.
- In the specification and claims, reference will be made to a number of terms that have the following meanings. The singular forms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise. Approximating language, as used herein throughout the specification and claims, may be applied to modify a quantitative representation that could permissibly vary without resulting in a change in the basic function to which it is related. Accordingly, a value modified by a term such as “about” is not to be limited to the precise value specified. In some instances, the approximating language may correspond to the precision of an instrument for measuring the value. Moreover, unless specifically stated otherwise, a use of the terms “first,” “second,” etc., do not denote an order or importance, but rather the terms “first,” “second,” etc., are used to distinguish one element from another.
- As used herein, the terms “may” and “may be” indicate a possibility of an occurrence within a set of circumstances; a possession of a specified property, characteristic or function; and/or qualify another verb by expressing one or more of an ability, capability, or possibility associated with the qualified verb. Accordingly, usage of “may” and “may be” indicates that a modified term is apparently appropriate, capable, or suitable for an indicated capacity, function, or usage, while taking into account that in some circumstances the modified term may sometimes not be appropriate, capable, or suitable. For example, in some circumstances an event or capacity can be expected, while in other circumstances the event or capacity cannot occur—this distinction is captured by the terms “may” and “may be.”
- The best mode for carrying out the innovative concept described herein has been described for purposes of illustrating the best mode known to the applicant at the time and enable one of ordinary skill in the art to practice the innovative concepts described herein, including making and using devices or systems and performing incorporated methods. The examples are illustrative only and not meant to limit the innovative concept described herein, as measured by the scope and merit of the claims. The innovative concept described herein has been described with reference to preferred and alternate embodiments. Obviously, modifications and alterations will occur to others upon the reading and understanding of the specification. It is intended to include all such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof. The patentable scope of the innovative concept described herein is defined by the claims, and may include other examples that occur to one of ordinary skill in the art. Such other examples are intended to be within the scope of the claims if they have structural elements that do not differentiate from the literal language of the claims, or if they include equivalent structural elements with insubstantial differences from the literal language of the claims.
-
- 1. Weitkunat, K., Schumann, S., Nickel, D., Hornemann, S., Petzke, K. J., Schulze, M. B., . . . Klaus, S. (2017). Odd-chain fatty acids as a biomarker for dietary fiber intake: a novel pathway for endogenous production from propionate. The American Journal of Clinical Nutrition, 105(6), ajcn 152702. https://doi.org/10.3945/ajcn.117.152702.
- 2. Řezanka, T., & Sigler, K. (2009). Odd-numbered very-long-chain fatty acids from the microbial, animal and plant kingdoms. Progress in Lipid Research, 48(3-4), 206-238. https://doi.org/10.1016/j.plipres.2009.03.003.
Claims (20)
1. A method for producing a poultry egg with an elevated amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) odd-chain fatty acids (OCFA), comprising:
culturing thraustochytrid cells to increase an amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids in the thraustochytrid cells compared to naturally occurring thraustochytrid cells, resulting in OCFA-rich thraustochytrid biomass that comprises a total amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids that is greater than 0.3% total fatty acid;
mixing a desired amount of OCFA-rich thraustochytrid biomass into poultry feed resulting in an OCFA-enriched feed composition, the desired amount being about 1.5-6.3% of the OCFA-enriched feed composition;
feeding the OCFA-enriched feed composition to poultry that lays eggs; and
retrieving an egg produced by the poultry, the egg comprising an elevated amount of OCFA in the lipid profile of the yolk, wherein the elevated amount of OCFA is an amount greater than 3% of the fatty acid profile of the yolk.
2. The method of claim 1 , wherein the thraustochytrid cells are Aurantiochytrium sp., Schizochytrium sp., Thraustochytrium sp., or Oblongichytrium sp.
3. The method of claim 1 , wherein the step of culturing thraustochytrid cells to increase the amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids in the thraustochytrid cells further comprises the steps of:
providing a culture medium;
adding thraustochytrid cells to the culture medium; and
adding propionic acid to the culture medium at a rate of at least 0.05 gram of propionic acid per gram of thraustochytrid cells.
4. The method of claim 1 , wherein the OCFA-enriched feed composition comprises a total amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids that is about 1.72% of the total fatty acid profile of the OCFA-enriched feed composition.
5. The method of claim 1 , wherein the poultry egg comprises over 400 mg of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids.
6. The method of claim 1 , wherein the step of culturing thraustochytrid cells to increase the amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids in the thraustochytrid cells further comprises the steps of:
providing a culture medium;
adding thraustochytrid cells to the culture medium; and
adding propionic acid to the culture medium at a rate of about 0.05-0.15 gram of propionic acid per gram of thraustochytrid cells.
7. The method of claim 1 , wherein the step of culturing thraustochytrid cells further comprises culturing the thraustochytrid cells in a two-stage axenic process, the two-stage axenic process comprising:
a first stage of adding dextrose or glucose as a growth carbon source; and
a second stage of adding propionate.
8. A method for increasing an amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids in an egg laid by a poultry animal comprising the steps of:
culturing thraustochytrid cells to increase an amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids in the thraustochytrid cells compared to naturally occurring thraustochytrid cells, resulting in OCFA-rich thraustochytrid biomass that comprises a total amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids that is greater than 0.3% total fatty acid;
mixing a desired amount of the OCFA-rich thraustochytrid biomass into poultry feed resulting in an OCFA-enriched feed composition, the desired amount being greater than 1% of the OCFA-enriched feed composition;
feeding the OCFA-enriched feed composition to the poultry animal that lays eggs; and
retrieving an egg produced by the poultry animal, wherein the egg comprises a total amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids that is greater than 3% of the total fatty acid profile of the egg yolk.
9. The method of claim 8 , wherein the thraustochytrid cells are Aurantiochytrium sp., Schizochytrium sp., Thraustochytrium sp., or Oblongichytrium sp.
10. The method of claim 8 , wherein the step of culturing thraustochytrid cells to increase an amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids in the thraustochytrid cells further comprises the steps of:
providing a culture medium;
adding thraustochytrid cells to the culture medium; and
adding propionic acid to the culture medium.
11. The method of claim 8 , wherein the poultry egg comprises about 250 mg to 1,000 mg of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids.
12. The method of claim 8 , wherein the OCFA-enriched feed composition comprises a total amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids that is about 1.72% of the total fatty acid profile of the OCFA-enriched feed composition.
13. The method of claim 8 , wherein the poultry egg comprises over 400 mg of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids.
14. The method of claim 8 , wherein the step of culturing thraustochytrid cells further comprises culturing the thraustochytrid cells in a two-stage axenic process, the two-stage axenic process comprising:
a first stage of adding dextrose or glucose as a growth carbon source; and
a second stage of adding propionate.
15. A method for producing a poultry egg with an elevated amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) odd-chain fatty acids (OCFA), comprising:
culturing thraustochytrid cells to increase an amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids in the thraustochytrid cells compared to naturally occurring thraustochytrid cells, resulting in OCFA-rich thraustochytrid biomass that comprises a total amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids that is greater than 0.3% total fatty acid;
mixing a desired amount of oil, derived from the OCFA-rich thraustochytrid biomass, comprising elevated concentrations of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids into poultry feed resulting in an OCFA-enriched feed composition, the desired amount of oil being at least 0.5% of the OCFA-enriched feed composition;
feeding the OCFA-enriched feed composition to poultry that lays eggs; and
retrieving an egg produced by the poultry, the egg comprising an elevated amount of OCFA in the lipid profile of the yolk, wherein the elevated amount of OCFA is an amount greater than 3% of the fatty acid profile of the yolk.
16. The method of claim 15 , wherein the thraustochytrid cells are Aurantiochytrium sp., Schizochytrium sp., Thraustochytrium sp., or Oblongichytrium sp.
17. The method of claim 15 , wherein the desired amount of oil is about 0.5% to 4% of the OCFA-enriched feed composition.
18. The method of claim 15 , wherein the desired amount of oil is about 1.5% to 6.3% of the OCFA-enriched feed composition.
19. The method of claim 15 , wherein the step of culturing thraustochytrid cells to increase the amount of pentadecanoic (C15:0) and heptadecanoic (C17:0) acids in the thraustochytrid cells further comprises the steps of:
providing a culture medium;
adding thraustochytrid cells to the culture medium; and
adding propionic acid to the culture medium at a rate of at least 0.05 gram of propionic acid per gram of thraustochytrid cells.
20. The method of claim 15 , wherein the step of culturing thraustochytrid cells further comprises culturing the thraustochytrid cells in a two-stage axenic process, the two-stage axenic process comprising:
a first stage of adding dextrose or glucose as a growth carbon source; and
a second stage of adding propionate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/073,075 US20210030024A1 (en) | 2018-09-21 | 2020-10-16 | Compositions and methods for introduction of odd-chain fatty acids into poultry eggs |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862734437P | 2018-09-21 | 2018-09-21 | |
US16/577,384 US10842173B2 (en) | 2018-09-21 | 2019-09-20 | Compositions and methods for introduction of odd-chain fatty acids into poultry eggs |
US17/073,075 US20210030024A1 (en) | 2018-09-21 | 2020-10-16 | Compositions and methods for introduction of odd-chain fatty acids into poultry eggs |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/577,384 Continuation US10842173B2 (en) | 2018-09-21 | 2019-09-20 | Compositions and methods for introduction of odd-chain fatty acids into poultry eggs |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210030024A1 true US20210030024A1 (en) | 2021-02-04 |
Family
ID=69884156
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/577,384 Active US10842173B2 (en) | 2018-09-21 | 2019-09-20 | Compositions and methods for introduction of odd-chain fatty acids into poultry eggs |
US17/073,075 Abandoned US20210030024A1 (en) | 2018-09-21 | 2020-10-16 | Compositions and methods for introduction of odd-chain fatty acids into poultry eggs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/577,384 Active US10842173B2 (en) | 2018-09-21 | 2019-09-20 | Compositions and methods for introduction of odd-chain fatty acids into poultry eggs |
Country Status (4)
Country | Link |
---|---|
US (2) | US10842173B2 (en) |
EP (1) | EP3852544A4 (en) |
CA (1) | CA3113649A1 (en) |
WO (1) | WO2020061445A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3897185A4 (en) * | 2018-12-21 | 2022-01-12 | Heliae Development LLC | Human and non-human animal use of microbial anaplerotic oil |
CA3124485C (en) | 2018-12-21 | 2021-12-07 | Heliae Development, Llc | Human and non-human animal use of microbial anaplerotic oil |
CN111567698B (en) * | 2020-06-11 | 2023-07-04 | 蜜儿乐儿乳业(上海)有限公司 | Feed additive, nutrition-enhanced feed, utilization method of nutrition-enhanced feed and nutrition-enhanced poultry eggs |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190194702A1 (en) * | 2017-12-22 | 2019-06-27 | Heliae Development, Llc | Anaplerotic oil production in microbials |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4918104A (en) | 1987-06-16 | 1990-04-17 | Weiss Howard S | Method and composition for increasing the concentration of omega-3 polyunsaturated fatty acids in poultry and poultry eggs and poultry and eggs resulting therefrom |
US5130242A (en) * | 1988-09-07 | 1992-07-14 | Phycotech, Inc. | Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids |
US7001610B2 (en) * | 2001-04-23 | 2006-02-21 | Omeganutrel Inc. | Food supplement and use thereof for elevating levels of essential fatty acids in livestock and products therefrom |
EP2211881A4 (en) | 2007-11-01 | 2012-01-04 | Wake Forest University School Of Medicine | Compositions and methods for prevention and treatment of mammalian diseases |
US8207363B2 (en) * | 2009-03-19 | 2012-06-26 | Martek Biosciences Corporation | Thraustochytrids, fatty acid compositions, and methods of making and uses thereof |
SG184437A1 (en) | 2010-04-06 | 2012-11-29 | Heliae Dev Llc | Methods of and systems for isolating carotenoids and omega- 3 rich oils from algae |
US20140193867A1 (en) | 2012-12-21 | 2014-07-10 | William Marsh Rice University | Microbial odd chain fatty acids |
FR3001736B1 (en) | 2013-02-06 | 2016-03-04 | Roquette Freres | BIOMASS OF MICROALGUE SCHIZOCHYTRIUM MANGROVEI AND METHOD FOR PREPARING THE SAME |
CN105555146A (en) | 2013-07-11 | 2016-05-04 | 康奈尔大学 | Algal-based animal feed composition containing exogenous protease animal feed supplement, and uses thereof |
US11077158B2 (en) * | 2014-07-17 | 2021-08-03 | Cornell University | Omega-3 fatty acid enrichment of poultry products with defatted microalgae animal feed |
KR101521274B1 (en) * | 2014-10-08 | 2015-05-22 | 에스케이이노베이션 주식회사 | Novel microalgae aurantiochytrium sp. la3 (kctc12685bp) and method for preparing bio-oil using thereof |
FR3038913B1 (en) * | 2015-07-17 | 2020-05-01 | Fermentalg | THRAUSTOCHYTRIDE BIOMASS, CULTURE METHOD AND USES |
GB201611497D0 (en) * | 2016-06-30 | 2016-08-17 | Devenish Nutrition Ltd | Compositions for use in enriching animal meat with omega-3 polyunsaturated fatty acids |
US20190112528A1 (en) * | 2017-10-13 | 2019-04-18 | Heliae Development Llc | Soil enhancement materials and methods |
-
2019
- 2019-09-20 US US16/577,384 patent/US10842173B2/en active Active
- 2019-09-20 WO PCT/US2019/052143 patent/WO2020061445A1/en unknown
- 2019-09-20 EP EP19862088.2A patent/EP3852544A4/en active Pending
- 2019-09-20 CA CA3113649A patent/CA3113649A1/en active Pending
-
2020
- 2020-10-16 US US17/073,075 patent/US20210030024A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190194702A1 (en) * | 2017-12-22 | 2019-06-27 | Heliae Development, Llc | Anaplerotic oil production in microbials |
Non-Patent Citations (2)
Title |
---|
Wang et al. "Dietary choline and phospholipid supplementation enhanced docosahexaenoic acid enrichment in egg yolk of laying hens fed a 2% Schizochytrium powder-added diet", 2017, Poultry Science, Vol. 96, pg. 2786–2794. (Year: 2017) * |
Wang et al. "Metabolic engineering to enhance biosynthesis of both docosahexaenoic acid and odd-chain fatty acids in Schizochytrium sp. S31", 08 Jun 2019, Biotechnology for Biofuels, Vol. 12, Article 141, pg. 1-14. (Year: 2019) * |
Also Published As
Publication number | Publication date |
---|---|
WO2020061445A1 (en) | 2020-03-26 |
US10842173B2 (en) | 2020-11-24 |
CA3113649A1 (en) | 2020-03-26 |
EP3852544A1 (en) | 2021-07-28 |
EP3852544A4 (en) | 2022-07-06 |
US20200093157A1 (en) | 2020-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210030024A1 (en) | Compositions and methods for introduction of odd-chain fatty acids into poultry eggs | |
Ginzberg et al. | Chickens fed with biomass of the red microalga Porphyridium sp. have reduced blood cholesterol level and modified fatty acid composition in egg yolk | |
Mendes et al. | Crypthecodinium cohnii with emphasis on DHA production: a review | |
Guedes et al. | Fatty acid composition of several wild microalgae and cyanobacteria, with a focus on eicosapentaenoic, docosahexaenoic and α-linolenic acids for eventual dietary uses | |
Singh et al. | Microbial production of docosahexaenoic acid | |
JP5762393B2 (en) | Yablet fungus, fatty acid composition, and methods of making and using the same | |
KR100277808B1 (en) | Lcd device and method for producig the same | |
JP2000513575A (en) | Method for producing docosahexaenoic acid and docosapentaenoic acid | |
KR20140019840A (en) | Methods of mutagenesis of schizochytrium sp and variant strains produced thereof | |
JP6715252B2 (en) | Process for enriching the biomass of a microalgae of the genus Thraustochytrium with DHA and with the amino acids ARG and GLU | |
Adamczak et al. | Properties and biotechnological methods to produce lipids containing conjugated linoleic acid | |
Cohen et al. | Single cell oils: microbial and algal oils | |
Sukenik et al. | Dietary lipids from marine unicellular algae enhance the amount of liver and blood omega-3 fatty acids in rats | |
Novotná et al. | Effect of Chlorella vulgaris and Japonochytrium sp. microalgae supplementation on composition and fatty acid profile of goat milk. | |
Nyberg | Analysis of fatty acids in egg yolks of various production systems | |
KR20100097568A (en) | The production method of egg and chicken contained of docosahexanoic acid(dha) with schizochytrium mangrovei mm103(kctc 11117bp) | |
Dhull et al. | Sources: plants, animals and microbial | |
Hajra et al. | Production of Egg with Low Cholesterol and High Omega-3 Fatty Acid through Dietary Manipulation | |
Vijayagopal et al. | Development of live feed enrichment product for marine fish larviculture | |
WO2017216818A1 (en) | Anaerobic growth of bacteria in unicellular alga | |
JP6938163B2 (en) | Lipid composition, its use and its production method | |
Nehra | Nutritional analysis of oleaginous algae from different reservoirs of Haryana and enhancement of its lipid and EPA yield | |
JP6362218B2 (en) | Yablet fungus, fatty acid composition, and methods of making and using the same | |
Chin et al. | The effect of dietary docosahexaenoic acid on the expression of lipogenic genes in broilers | |
Iyapparajanarasimapallavan | Propensity of bioenrichment protocol in marine ornamental fish larviculture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
AS | Assignment |
Owner name: HELIAE DEVELOPMENT, LLC, ARIZONA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EVANS, JAMIE;LAMONT, MICHEAL;REEL/FRAME:055447/0917 Effective date: 20191122 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |